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1. Sin3 a historical journey: 
The research leading to Sin3 started in yeast with a transcriptional activator called 
SWI5 that is normally required for the expression of the HO gene (1). During mitosis 
Saccharomyces cerevisiae divides into two cells, a mother cell and a daughter cell. 
HO is expressed exclusively in the mother cell (2). Surprisingly when SWI5 was 
mutated, the HO gene was silent. Sin3 (Swi5 Independent) was picked up in a screen 
as the candidate which when mutated restored the expression of HO gene. Notably, 
HO in this SIN3 mutant was now expressed in daughter cells (3,4). Sin3 was 
subsequently identified as a negative regulator of SPO13, SPO11 (required for 
sporulation), TRK2 (a potassium transporter), PHO5 (encodes an acid phosphatase), 
INO1 (inositol 1-phosphate synthase), FUS1 (required for mating) and IME2 (inducer
of meiosis) (5-8). While this mutant screen experiment suggested that Sin3 was a 
negative regulator, mechanism behind these observations remained elusive.  
Sin3 and repression of transcription: 
A few years later, the fusion protein LexA-Sin3 was shown in yeast to repress a LacZ
reporter gene containing LexA binding sites (9). At the same time a mutation screen 
was performed with IME1 (inducer of meiosis). Sin3 was again picked up as well as 
Rpd3 (reduced potassium dependency) and Ume6 (8). Many years later using 
immunoprecipitation and yeast two hybrid experiments Sin3, Rpd3 and Ume6 were 
shown to form a complex (10). Rpd3 was identified to be a homolog of human histone 
deacetylases (HDAC) and Ume6 was identified as a DNA binding protein. It was 
shown as well that the repression by Sin3 was Rpd3 dependent and an artificial 
recruitment of Rpd3 to DNA resulted in transcriptional repression.
The Myc/Mad/Max network brings Sin3 in connection with a tumor suppressor: 
Parallel to yeast studies, research on Sin3 in higher eukaryotes provided major 
advances in our understanding of transcriptional repression. Myc family proteins (N-
Myc, C-Myc and L-Myc) are proto-oncogenes and promote proliferation of the cells. 
Myc and Max are basic helix leucine zipper proteins, which interact as an heterodimer 
and bind to DNA specific hexanucleotide core elements CACGTG, called E-box. The 
Myc/Max heterodimer is present in proliferative cells, and plays a role in 
transcriptional activation. In eukaryotes, an interaction screen for Max interacting 
proteins was performed and Max binding partners Mad1, Mad3, Mad4 and Mxi1 were 
discovered (11-13). Moreover in vivo transcription assay showed that Myc/Max 
activates transcription, whereas Mad/Max represses transcription suggesting that Mad 
played a central role in balancing Myc/Max’s action. Ayer et al and Zervos et al using 
the U937 cell line detected Mad/Max heterodimer upon induction of macrophage 
differentiation (12,14). Mad was one year later defined as a tumor suppressor when 
the Eisenman and DePinho labs showed that Mad affects proliferation of non 
transformed cells and blocks cooperative transformation by Myc and Ras (15-20). The 
same functional properties could be attributed to Mxi1, Mad3 and Mad4 
(13,15,16,21). As for the early studies in yeast with Sin3, the mechanism by which 
Mad represses transcription remained elusive. The breakthrough came in 1995 when 
Mad and Mxi1 were used as “baits” in yeast two hybrid screens and mSin3a and 
mSin3b were picked up as interactors (22,23).
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Histone deacetylases, the basis of transcriptional repression by Sin3:
The question of how mSin3 triggers transcriptional repression was still open. In 1996 
Rpd3 was shown to be a homolog of human HDAC2. Furthermore, in yeast, Sin3, 
Ume6 and Rpd3 were picked up in the same IME1 screen (5,8,24,25). Yang et al 
showed that the DNA binding protein YY1 mediates transcriptional repression by 
interacting with HDAC2. Therefore, transcriptional repression could potentially 
involve Mad, Sin3 and HDAC2. In 1997, one year after Taunton et al, it was shown 
that HDAC1 and HDAC2 are part of a complex with Mad and mSin3 (26,27). A 
similar complex could subsequently be purified from yeast containing Sin3, Ume6 
and Rpd3 the yeast homolog of HDAC1 (10). In order to show that HDAC1 and 
HDAC2 were at the basis of the mechanism of transcriptional repression by Sin3, 
HDAC inhibitors called trapoxin, TSA (trichostatin A), Na butyrate were used in 
reporter assays in vivo. The targeting of mSin3 to a reporter resulted in repression of 
transcription. Upon addition of HDAC inhibitors, repression was relieved and high 
level of the reporter gene activity was observed, suggesting that the enzymatic activity 
of the histone deacetylase was the key to the mechanism for transcriptional repression 
by mSin3 (26-29).  
Histone acetylation versus Histone deacetylation: 
Excitement around histone deacetylation by HDAC was triggered by the possible 
interplay with the histone acetyl transferase activity (HAT). A new piece of the puzzle 
came from the discovery that Myc copurifies with a nuclear cofactor called TRRAP 
(transformation/transcription domain-associated protein) (30,31). Parallel to studies in 
mammals a close homolog to TRRAP was identified in the yeast Saccharomyces
cerevisiae SAGA complex. And surprisingly the SAGA complex contains a HAT, 
GCN5 (32). Shortly thereafter, the mammalian homolog of GCN5 was identified as 
the interacting partner of the c-Myc cofactor TRRAP (33-36). The Myc/Mad/Max 
network was hypothesized to be a balanced mechanism. The Myc/Max heterodimer 
recruiting TRRAP-HAT, activates genes in proliferating cells and at the opposite side, 
the Mad/Max heterodimer present in differentiated cells, recruits the Sin3/HDAC 
complex leading to gene repression.  
2. The door to transcription regulation: chromatin structure, nucleosomes, 
histones, the histone code: 
The Human Genome consists of 3 billion base pairs and about 32 000 protein 
encoding genes. To fit into the cell nucleus, such a large amount of information is 
compacted 10 000 fold into a structural polymer called chromatin and organized in 
many small modules called nucleosomes. Chromatin is generally subdivided into two 
types; actively transcribed region called euchromatin and transcriptionally repressed 
regions called heterochromatin. 
Nucleosomes consist of an histone octamer composed of two molecules each of the 
core histones H2A, H2B, H3 and H4 wrapped around 146 bp of DNA in a 1 ¾ 
superhelical turns (fig. 1) (37).
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Figure 1. Crystal structure of the nucleosome to a resolution of 2.8Å. Only one turn of the DNA 
around the nucleosome is shown (37). 
The fact that DNA is wrapped around nucleosomes creates a barrier for decoding the 
nucleotide information contained in the genome. Histones are like doors and contain 
an electronic key the flexible amino-terminal tail. One code ultimately allows the 
opening of the door, decondenses nucleosomes and allows access to DNA information 
while a different code closes the door by folding DNA into a compact and 
inaccessible structure. The histone tails contain a complex code and are the platform 
for the docking of many enzymes. The code is created by various enzymes to generate 
combinations of post translational modifications including acetylation, 
phosphorylation, methylation, sumoylation, ubiquitylation and ADP-ribosylation (38). 
Moreover the histone code facilitates interaction with other proteins which act to 
remodel chromatin (39).  
Acetylation of histone tails has long been correlated with increased transcription (40). 
HAT enzymes use acetyl-CoA to transfer acetyl group on lysine leading to a 
neutralization of the positive charge and to an increase in the hydrophobicity. 
Acetylation is thought to loosen the contact between histone tails and nucleosomes. 
p55 was the first nuclear HAT identified in the ciliated protozoan Tetrahymena using
in gel activity assay (41). p55 is having a significant homology with the sequence of 
yGcn5 known at that time as a yeast transcriptional regulator (42-47). Subsequently, 
several homologs of GCN5 in human and other organism were discovered and cloned 
and showed to be HATs such as human GCN5, PCAF(p300/CPB-associated factor). 
Other HATs family members include the two close related p300 and CBP (CREB-
binding protein) involved in the transcription initiation. hTAFII250, TFIIIC and the 
sachacharomyces cerevisiae nut1 component of the mediator complex are considered 
to be general transcription factor that contain HAT activity (48-54). 
Insight into the histone code was gained with experiments using yeast GCN5 in vitro
on recombinant histones and showed acetylation of lysine 14 on histone H3 and of 
lysine 8 and 16 on histone H4 (55) (fig. 2). However GCN5 is poorly active on 
nucleosomal templates and needs the presence of subunits of the co-activator 
complex: In the context of a complex such as SAGA, GCN5 acetylates in vitro lysine 
residues 9, 14, 18 and 23 of histone H3 and has also some activity towards H2B as 
opposed to GCN5 in the context of NuA4 which acetylates lysine residues 5, 8, 12 
and 16 of H4 and lysine 5 of H2A. In the context of the ADA complex, GCN5 
acetylates H3 lysine residues 9, 14 and 18 (56,57). Therefore GCN5 can have a 
different histone and lysine specificity depending on the subunits complex it is 
associated with.  
NuA3 with the Sas3 catalytic subunit acetylates strongly lysine 14 of histone H3 (58). 
Human GCN5 and PCAF complex preferentially acetylate H3 at lysine 9 and 14 
whereas human NuA4 preferentially acetylates H4 at lysine 4, 8, 12 and 16. Preferred 
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acetylation sites for Tip60 complex in vitro are the lysine 5 of histone H2A, the lysine 
14 of histone H3, and the lysine 5, -8, -12 and 16 of histone H4 (59). 
       Ac  Ac
        |   | 
H2A SGRGKQGGKARAKAKTRSSR 
        5   9 
        Ac     Ac  Ac  Ac 
        |      |   |   | 
H2B PEPSKSAPAPKKGSKKAITKA 
        5      12  15  20 
           Ac   Ac  Ac   Ac 
           |    |   |    |
H3 ARTKQTARKSTGGKAPRKQLATKAARKSAPA 
           9    14  18   23
       Ac Ac  Ac  Ac 
       |  |   |   | 
H4 SGRGKGGKGLGKGGAKRHRK 
       5  8   12  16
Figure 2.  Histone Lysine sites of histone acetylation.
The HAT associated with the MSL complex in Drosophila, MOF, acetylates lysine 16 
of histone H4 in order to maintain the chromosome X highly expressed in male 
dosage compensation (60).  Remarkably, p300/CBP acetylates all four histones and 
shows a multisite acetylation pattern despite an in vivo H4 preference for CBP on K12 
and a preference for p300 on K8 (61). Furthermore, the histone code next to 
acetylation includes combinations of mono- di-, tri-methylated, ubiquitinated and 
phosphorylated histone marks with a challenging complexity. 
3. Histone deacetylases 
In contrast to the histone acetylation which is primarly correlated with transcriptional 
activity, the deacetylation of histone is linked to repression. Histone deacetylase 
(HDAC) are key enzymes in this process and can be subdivided into three classes. 
Human class I histone deacetylase category includes HDAC1, HDAC2, HDAC3 and 
HDAC8. The first HDAC isolation performed in Taunton’s lab used trapoxin, an 
HDAC inhibitor as an affinity matrix to purify associated human nuclear proteins. 
The HD1 cDNA sequence (HDAC1) was identified and was strikingly homologous to 
yeast repressor RPD3 (24,62). HDAC1 is also 85% identical in protein sequence with 
HDAC2, and both are part of the multiprotein complexes Sin3 and Mi-2/NuRD 
(Nucleosome Remodelling Histone Deacetylase). HDAC3 shares ~52% sequence 
identity at the protein level with HDAC1 or HDAC2 and is a component of the 
SMRT/N-CoR co-repressor complexes (63,64). Interestingly, HDAC8 a recently 
identified member of the class I HDACs  associates with the acute myeloid leukeamia 
translocation product Inv16 (65-68).
The class II HDAC includes HDAC4, 5, 6, 7, 9 and 10. They were classified on the 
basis of their homology to yeast HDAC HDA1 (69,70). The class II HDACs shuttles 
between the nucleus and the cytoplasm. The catalytic domain of class II HDACs is 
located at the C-terminus and shares similarities with the class I HDAC catalytic 
General introduction
15
domain. The recently identified HDAC11 shows homology to the catalytic domain of 
class I and class II HDACs (71). HDAC11 is expressed in specific tissue heart, brain, 
skeletal, muscle and kidney and is localized predominantly in the nucleus. HDAC11 
is associated with HDAC6 which functions as a tubulin deacetylase (72). 
The class III HDACs (or sirtuins) are defined by their homology to the yeast Sir2 
(Silent Information Regulator) and their dependence of a NAD+ substrate for activity. 
The class III HDACs shows no homology to class I or class II HDACs but to a group 
of prokaryotic enzymes. Sirtuins are characterized by the HDAC and ADP-ribosyl 
transferase activity (73,74). So far seven sirtuins have been discovered in human 
SIRT1 to SIRT7 but their function is not clear. In contrast to class I and class II 
HDACs, sirtuins are insensitive to classical HDAC inhibitors such as trichostatin A. 
Yeast Sir2 is so far the best characterized sirtuin protein and plays a role in 
transcriptional silencing at telomeres and maintenance of genome integrity at rDNA 
locus (75). SIRT1 the human homolog of yeast Sir2 was recently shown to have a 
substrate specificity on K14 of H4, K9 of H3 and K26 of H1 (76).
4. Sin3, a platform for transcription factors: 
Sin3 is a large acidic protein present in the nucleus of eukaryotic organisms. In yeast 
Sacharomyces cerevisiae, Sin3 is expressed as one isoform in contrast to the more 
evolved Schizosacharomyces pombe which has three Sin3 isoforms called Pst1, Pst2 
and Pst3 or to mammals which have two isoforms Sin3a and Sin3b (77). 
Schizosacharomyces pombe Pst1 is the isoform with the highest homology to Sin3 
from budding yeast, whereas Pst2 and Pst3 seem to have emerged by duplication early 
in evolution. Drosophila megalonaster and Xenopus databases have so far only one 
Sin3 isoform annotated (78). Sin3a is the largest human isoform with an estimated 
molecular weight of 145 kDa and 1273 amino acid residues in contrast to human 
Sin3b which has a shorter amino terminal region, a molecular weight of 129 kDa and 
1130 amino acid residues. To add further complexity splice variants occur for both 
Sin3a and Sin3b in human and mice and four splice variants of Sin3 have been 
reported in Drosophila (28,79). The precise functional role of the different Sin3 
isoforms and splice variants remains to be investigated. 
Interestingly, the primary structure of Sin3 shows the presence of four conserved 
amino acid repeats (fig. 3). This repeat motif was predicted in 1990 to consist of two 
amphipatic D-helices separated by a 20 amino acid spacer (80). This motif was shown 
to be present also in TPR (tetratricopeptide motif repeat) or in helix loop helix 
dimerization domains of members of the Myc protein family. Although the 
conservation in hydrophobic amino acid conservation is overall very low, it suggested 
that the paired amphipatic helix domains (PAH) of Sin3 were involved in protein-
protein interaction. The structure of PAH2 showed that this domain consisted of four 
rather than two amphipatic D-helices (81-83).
Other conserved regions present in Sin3 include the HID region (SDS3 and HDAC 
interacting domain) located between the PAH3 and PAH4 domain, and the C-terminal 




Figure 3. Structural features of Sin3. (A) Schematic representation of mSin3a and mSin3b. 
PAH(Paired amphipatic helix) domains and HID (SDS3 and Histone deacetylase) domain and their 
percentage identity between mSin3a and mSin3b are shown. (B) Sequence alignement of the four PAH 
domains of mSin3b. 
4.1 The core subunits of the Sin3 complex: 
The mSin3a complex was first purified in 1997 from HeLa cells and resulted in the 
identification of the co-purifying proteins HDAC1, HDAC2, RbAp46, RbAp48, 
SAP30 (Sin3 Associated Polypeptide) and SAP18 (84).
RbAp46 and RbAp48 which share 90% homology, belong to WD-repeat protein 
family and were originally isolated using immobilized retinoblastoma protein (Rb) 
(85-87). Remarkably Rb-associated proteins interact with histone H4 and H2A and 
may therefore play a role in the stabilization of the Sin3/HDAC interaction with 
histones (88). Sap30 was shown to interact with HDAC1 and Sin3 and may therefore 
help in stabilizing the Sin3 complex (89). Sap18 was first purified by Zhang and his 
colleagues, as a core protein of the mSin3a complex, but this assignment remains 
questionable, as other reports showed that Sap18 included in the ASAP (Apoptosis-
and Splicing Associated Protein) complex plays a role in RNA processing and 
apoptosis (90).
More recently, SDS3 (Suppressor of Defective Silencing 3) was shown to be a core 
subunit of the Sin3/RPD3 complex in the yeast (91,92) and mouse Sin3a complexes 
(93). SDS3 interacts via the Sin3/HDAC interacting domain (HID) and promotes the 
integrity of the Sin3/RPD3 complex and has been suggested to be essential for the 
catalytic activity of the Sin3/HDAC complex (93-95). A function of mSDS3 was 
suggested by using SDS3 deficient cells which showed failure in deacetylation and 
methylation of pericentric heterochromatin, aneuploidy and defective karyokinesis. 
Remarkably, mSDS3 could rescue this phenotype and only in the presence of the 
mSin3 binding domain of SDS3 (96). 
Sin3 is a regulator of transcription but lacks DNA binding activity and needs therefore 
transcriptional repressors to be targeted to gene promoters. A large body of data 
suggests that PAH2 (paired amphipathic helix) and to a lesser extend the PAH1 
domain of Sin3 fulfills a critical role in the recruitment of transcriptional repressors. 
The structural properties and function of PAH1, PAH2 and their interacting repressors 
will be discussed in detail, in the subsequent sections. 
mSin3a
mSin3b
114 189 295 383 451 526 872 955 12821
PAH1 PAH2 PAH3 PAH4HID
25 100 145 230 285 358 384 484
551 651
1 954697 788





4.3 PAH2 interacting proteins: 
4.3.1 Mad family members: 
Biological function of Mad family members: 
Myc/Mad/Max are proteins of the basic helix-loop-helix-leucine zipper (bHLHZip) 
family. The bHLHZip domain provides an interaction surface with DNA at E-box 
hexanucleotide elements CACGTG dispersed throughout the genome. Mad1, Mxi1, 
Mad3 and Mad4 originally identified in screens looking for Max binding partners, 
form heterodimers with Max, and bind the same E-box as Myc/Max heterodimer (11-
13). As opposed to Myc/Max, Mad/Max heterodimer represses E-box dependent 
genes (11-13,23).
Many experiments in different cell types have established a correlation between 
terminal differentiation and upregulation of Mad family members expression such as 
in chondrocytes, colonic epithelia, epidermal keratinocytes, adipocytes, motor 
neurons, myeloid and erythroid hematopoietic cells (12,14,19,97-103). The role of 
Mad family members is corroborated and extended by in situ hybridization of mouse 
embryonic tissues (skin, bone, colon, neural tube, brain retina and thymus) at different 
stages of development. Myc expression remains limited to the proliferating precursor 
layer, in contrast to Mad4 which is detected at high levels in the differentiated cell 
layer. Mad1 expression appears to be restricted to cells late in differentiation whereas 
Mad3 expression is restricted to S phase of proliferating cells. By using hematopoeitic 
cell lines and chemical treatment in vitro that induces terminal differentiation, high 
levels of Mad and Mxi1 mRNA were shown. In agreement with this observation, a 
switch can be documented from Myc/Max to Mad/Max complex upon induction of 
differentiation (12,14,97,99). Moreover, studies in mice overexpressing Mad, under 
the control of the E-actin promoter, resulted in erythroid and myeloid progenitors cells 
with reduced proliferative capacity. Mouse embryonic fibroblast derived from these 
mice showed a three fold increase in their doubling time after reentry in the cell cycle 
following G0 arrest, suggesting that Mad overexpression leads to a quiescent state 
(20).
Despite an important role in differentiation and tumor suppression, knockouts of Mad, 
Mad3 and Mxi1 resulted in viable and fertile mice. The granulocytic lineage of the 
Mad1 null mice was shown to be delayed in its ability to exit the cell cycle prior to 
differentiation and Mad3 knockout showed extra sensitivity to gamma irradiation.  
Redundancy with other Mad family members might account for these modest 
phenotypes especially in Mad1 and Mxi1 knockout mice because Mad3 and Mxi1 
mRNA transcript levels were shown to be strongly upregulated in tissues where they 
are not normally expressed (102,104,105). Significantly, Mxi1 knockout mice 
displayed an increase susceptibility to tumorigenesis after treatment with the 
carcinogen DMBA (9,10-dimethyl-1,2-benzanthracene), by forming B cell 
lymphomas and squamous cell carcinomas, strongly suggesting that Mxi1 plays an 
important role in regulating cellular proliferation. 
Functions and structural features of the Mad -Sin3 interaction domain: 
A striking functional characteristic of Mad family members (Mad1, Mxi1, Mad3 and 
Mad4) is their ability to interfere with the proliferation of non transformed cells as 
well as to block the transformation by Myc and Ras oncogenes when overexpressed 
(13,15-20,106). Furthermore, in yeast, when tethered to Gal4, Mad was shown to 
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repress transcription of a reporter gene in a Sin3 dependent manner (107). It 
highlights therefore two functional roles for Mad: tumor suppression and repression 
of transcription. These activities of Mad have been shown to be dependent on a small 
region named SID (Sin3 Interaction Domain) (18,23). The SID sequence, as it was 
functionally determined in Mad1 is highly conserved within its family members 
(Mad1, Mad3, Mad4, Mxi1 and Mnt) and located at the N-terminus between residues 
8-20 (table 1).
    protein name                           Sequence 
Hs/Mm Mad1       5-VRMNIQMLLEAADYLERRERE-25
Hs/Xl Mad4       2-ELNSLLILLEAAEYLERRDRE-22
Mm    Mad4       2-ELNSLLLLLEAAEYLERRDRE-22
Mm    Mad3       2--ASNIQVLLQAAEFLERRERE-24
Hs/Mm Mxi1       5-KMINVQRLLEAAEFLERRERE-25
Rn    Mxi1       5-KMINVQPMLEAAEFLERRERE-25
Dr    Mxi1        23--NVQVLLEAASYIESAERK-40
Hs/Mm Mnt         1-MSIETLLEAARFLEWQAQQ-19
Ce    Mad         6-LNLGHLLTAARLLDIGALD-23
Consensus Mad family 
members           ZtMZZMMXAAXXMnXXn
Hs    Pf1       207-RRPFELLIAAAMERNPTQF-225
Sc    Ume6       515-KLDDDLGTAAAVLSNMRSS-533
Hs    TIEG1/KLF10        33-TAEKSDFEAVEALMSMSCW-51
Hs    TIEG2/KLF11        22-ILEQTDMEAVEALVCMSSW-40
Hs    BTEB1/KLF9         3-AAAYMDFVAAQCLVSISNR-21
Hs    BTEB3/KLF13         3-AAAYVDHFAAECLVSMSSR-21
Hs    BTEB4/KLF16         3-AVACVDYFAADVLMAISSG-21
Hs    HBP1       358-DFTPMDSSAVYVLSSMARQRRAS-380
Table 1: Sin3 interaction domain (SID) sequences of PAH2 interacting proteins. In consensus 
sequence, M stands for a bulky hydrophobic residue, X for a non proline residue, Z for a large residue 
with a significant aliphatic component, n for a negatively charged residue and t for a small residue. 
Figure 4. Amphipatic helical wheel of Mad SID (7-20). 
The SID of Mad contacts the PAH2 domain of Sin3 and folds as an amphipatic helix 
(fig. 4). Introducing proline residues in the SID of Mad caused a loss of repressor 
function in GAL4 reporter assays and additional mutations in the hydrophobic face of 
the Mad SID helix affected the interaction with PAH2, while no effect was observed 
with mutations in the hydrophilic face. These experiments demonstrate the 
importance of hydrophobicity and D-helical conformation of the N-terminus region of 
Mad for its association with the Sin3 complex (22,108).  
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A structural basis for the association between Mad and the PAH2 has been provided 
with NMR experiments. The PAH2 domains of mSin3a and mSin3b adopt a four 
helix bundle structure and define a compact domain with an extensive hydrophobic 
core (81-83,109,110). Residues 152-167, 172-189, 202-212 and 217-226 of PAH2 of 
mSin3b form the four helices H1, H2, H3 and H4 while residue 168-171 and 213-216 
fold into turns (fig 4A). In mSin3a residues 302-317, 322-345, 355-365 and 370-377 
form the four helices H1, H2, H3 and H4 of PAH2 respectively (fig. 5A and D). In 
both mSin3a and mSin3b H1 and H2 are approximately coplanar with a ~45° angle. 
H2 and H3 are antiparallel while H4 is tilted at an angle of 15° with H1. Remarkably, 
in the PAH2 structure of mSin3b, residues 190-201 form a large loop between H2 and 
H3 in contrast to the H2/H3 loop of mSin3a, which is smaller in length (fig. 5C). 
Differences are further seen in a longer H2 helix in mSin3a, as compared to the H2 
helix of mSin3b, suggesting higher H2 helix propensity in mSin3a.  
The Mad1-SID amphipatic helix is located between H1 and H2 at an angle of 45° 
with respect of H2. PAH2 has an extensive hydrophobic core contacting extensively 




mad1:   VRMNIQMLLEAADYLERREREAEHGYAS 
msin3a:    ****** **  **
msin3b:   * ***** **  **  *
C                                                   D 
Figure 5. (A) Sequence alignment of the PAH2 domain of mSin3a and mSin3b. Helix mapped from 
the structure of mSin3a and mSin3b are shown under as rectangles. Stars identify contact residues 
involved in the PAH2/Mad Interaction with either mSin3a or mSin3b. (B) Mad1-SID (5-33) sequence.  
Stars identify Mad1 –SID contact residues involved with PAH2 domain of either mSin3a or mSin3b 
(C) Ribbon diagram of the structure of the PAH2 domain of mSin3b(grey) in complex with the Mad-
SID(5-24) (black). Diagram was adapted from PDB structure 1PD7 using YASARA(81). (D) Ribbon 
diagram of the structure of the PAH2 domain of mSin3a(grey) in complex with the Mad-SID(6-21) 
(black). Diagram was adapted from PDB structure 1S5R using YASARA(81). Helices of PAH2 are 
indicated.
Interestingly, NMR spectra of the unbound and bound state of the Sin3b PAH2 
domain in complex with Mad1 SID showed large differences in chemical shifts, 
primarily in the first two turns of H1 (especially at residue 152 and 154 of H1 of 












CD spectra of Mad1-SID in a free state did not much reveal secondary structure, 
therefore it is tempting to speculate that upon PAH2 binding, Mad-SID undergoes a 
conformational change to acquire an helical fold (108). 
To get insight into the binding of Mad-SID with PAH2, PAH2 mutational analysis of 
mSin3a was performed by Eisenman and colleagues and tested in GST-pulldown 
assays. These experiments confirmed that conserved hydrophobic residues I308, 
V311, L329, L330 are involved in the binding of the Mad SID. Even though the 
majority of contacts between Mad and PAH2 involve hydrophobic amino acids, a few 
hydrophilic residues have been shown to be important for binding to the Mad-
SID(81,82). K315 in mSin3a contacts E20 while K165 in mSin3b contacts E20 and 
E23 in the Mad SID (fig. 5B), showing therefore that electrostatic interactions are also 
important for association between Mad-SID and PAH2.  Other experiments have 
underlined an important role in the length of the Mad-SID. Surface plasmon 
resonance experiment with PAH2 of mSin3b yielded a Kd of 0.2 PM for Mad-SID (5-
35) and of 1.4 for Mad-SID (5-20), while beta galactosidase quantitative assays in 
yeast two hybrid showed a 1.8 fold increase in PAH2 level of interaction with Mad-
SID (1-27), compared to Mad-SID (8-20) (81,108). These studies suggest that a 
longer Mad-SID has a higher affinity. Interestingly, mutation of the PAH1 domain of 
mSin3a at L127P/L130P was reported to reduce the interaction between Mad1-SID 
and PAH2 whereas PAH3 and PAH4 were not effected, therefore suggesting that 
PAH1 might have a helping function in allowing Mad to interact with PAH2 (111). 
Myc/Mad/Max and target genes: 
E-box cis-acting elements are widely present throughout the human genome and have 
been reported to mediate regulation by the Myc/Mad/Max network. Human 
telomerase reverse transcriptase (hTERT), Id2 and cyclin D2 are among the regulated 
genes (112-114). Application of chromatin immunoprecipitation (ChIP) approaches 
showed recruitment of Myc/Max heterodimers to E-box elements of these promoters 
in proliferating cells. Upon differentiation of HL60 cells Myc/Max heterodimers are 
replaced by Mad/Max heterodimers. The recruitment of Myc/Max heterodimers 
correlates then with a high transcription level, the presence of TRRAP and high 
acetylation level of H3 and H4 on the promoters studied in proliferating cells. In 
contrast  Mad/Max was shown to be present on promoters from differentiated cells, 
correlating then with a reduced level of acetylation of H3 and H4 and transcriptional 
repression, indicative of recruitment of the Sin3/HDAC complex by the Mad/Max 
heterodimer (112). 
A challenge ahead is defining all target genes of the Myc/Mad/Max network. An 
elegant approach in which dMyc, dMnt or dMax are fused to a bacterial DNA 
methylase and are expressed in drosophila Kc cells recently revealed new target 
genes. Dam methylase, allows isolation of fragments containing Myc/Mad/Max 
members.  Hybridization of the isolated fragments on a cDNA microarray showed 73 
shared target genes.  Studying in detail a target, the Bicaudal (bic) gene, one could 
observe with ChIP correlation of dMyc binding with acetylation of H3 and H4 while 
dMnt binding correlated with a reduced level in acetylation of H3 and H4 (115). 
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4.3.2 Sp1-like repressor proteins and the alternative A/VXXL consensus motif: 
The Sp1-like family of transcription factors is characterized by the presence of three 
highly conserved C-terminal zinc finger motifs which are capable of binding to GC-
rich DNA elements. Sp1-like proteins comprise many members of which TIEG1, 
TIEG2, BTEB1, BTEB3 and BTEB4 have been shown to contain an N-terminal SID 
that interacts with the PAH2 domain of mSin3a. The SID of SP1-like members can 
facilitate recruitment of mSin3a/HDAC and result in the repression of transcription 
activity in reporter assays. CD spectroscopy has shown that the SID of SP1-like 
members can indeed adopt an alpha helical conformation. Strikingly the SID in SP1-
like members is defined by an A/VXXL consensus motif in contrast to Z-
tMZZMMXAAXXMnXXn consensus of Mad family members SIDs, suggesting 
therefore that PAH2 can accommodate several motifs (table 1) (116).  Furthermore, a 
model of the 3D structure of the TIEG2-SID in complex with PAH2 obtained by 
molecular dynamics analysis reveals a preference for the D-helix of the TIEG2-SID to 
be parallel to H2 of the PAH2 domain of mSin3a, in contrast to the D-helix of the 
Mad-SID which is located between H1 and H2 at an angle of 45° in respect of H2 
(117). Contact residues could be depicted and confirmed by GST pulldown assays; 
the map in figure 6A shows the potential interacting residue (fig. 6A). In conclusion, 
different SIDs can bind PAH2 in different orientations (compare fig. 6A and B).
Another feature of TIEG2 is the regulation of binding of the SID to mSin3a through 
phosphorylation of four S/T residues adjacent to the SID by the (EGF)-Ras-MEK1-
ERK2 signaling pathway (118). An impaired binding with mSin3a and a loss of 
repression function was shown upon phosphorylation of TIEG2. This is so far the 
only case in which regulation of binding to the PAH2 domain by signaling was 
shown. Interestingly, a polymorphic Gln62Arg variant of TIEG2 was shown to 
associate with type II diabetes mellitus patients and to alter Sin3A binding to TIEG2 
(119). Thus, a loss of interaction between TIEG2 and Sin3a may contribute to the 
development of diabetes. 
A
B
Figure 6. (A) Schematic representation of potential interacting residue between TIEG2 and the PAH2 
domain of mSin3a. Helices of PAH2 are indicated. Predicted interacting residue from model 1PO7 are 
depicted with connected lines (117). (B) Schematic representation of the intermolecular NOEs 
observed in the PAH2–hMad1-SID complex. Helices 1 and 2 of PAH2 of mSin3b are shown at the 
bottom of the figure, and helices 3 and 4 of PAH2 of mSin3b are shown at the top of the figure. 
Residues involved in intermolecular NOEs are indicated with connecting lines. Helical regions and 
solvent accessibility, as calculated by the program PROCHECK-NMR22, are indicated by the yellow 
ribbon and the blue bars, respectively (dark black indicates low solvent accessibility). Figure based 
from Spronk et al (83). 
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4.3.4 HBP1 and the inverted helix: 
HBP1 is an HMG-box-containing transcriptional repressor which has functional roles 
in cell cycle progression from G1 to S phase, tumor suppression and in p38 MAP 
kinase pathway (120). HBP1 associates with the pocket binding proteins p130, Rb and 
consequently HDACs. Recently HBP1 was also shown to contact HDAC in an Rb 
independent manner through mSin3a. The SID of HBP1 as opposed to Mad and SP1-
like members is located in the middle of HBP1 between residue 358 and 380 and has 
a moderate affinity for PAH2 with a Kd of ~5 PM (110). The HBP1 SID can mediate 
repression of transcription in a TSA sensitive manner in reporter assays. Remarkably, 
the SID of HBP1 and SP1 like members, contain the AA/VXXL consensus sequence 
which bears poor similarity to the SIDs of Mad family members (table. 1).  




Mad1 SID       6-RMNIQMLLEAADYLER-21
     MxxMMxAA
Figure 7.  (A) Ribbon diagram of the structure of the PAH2 domain of mSin3a (grey) in complex with 
the Mad-SID (5-24) (black). Diagram was adapted from PDB structure 1S5Q using YASARA. (B) 
Ribbon diagram of the structure of the PAH2 domain of mSin3a (grey) in complex with the HBP1-SID 
(358-380) (black). Diagram was adapted from PDB structure 1S5R using YASARA. N and C terminus 
of the SID amphipatic helix are indicated. (C) Sequence of the PAH2 domain of mSin3a and HBP1 
SID. Helix mapped from the structure of mSin3a are shown under as rectangles. Stars identify contact 
residues involved in the PAH2/HBP1 SID Interaction. (D) The paradox of a reverse helix. Reverse 
sequence of HBP1 SID is aligned with Mad1 SID sequence. Underlined residues share identical contact 
residues in PAH2. 
The structural analysis of the HBP1-SID in complex with the PAH2 domain of 
mSin3a revealed several interesting findings: First, NMR and CD spectroscopy 
experiment showed that the HBP1 SID like the Mad1 SID is unfolded in a free state 
or folded as an amphipatic helix when in complex with the PAH2 domain. Secondly, 
as for the Mad1-SID, H1 of PAH2 is crucial because when disrupted, the interaction 
is lost. Finally, NMR revealed a remarkable opposite N-term to C-term orientation of 
the HBP1 SID helix as compared to the Mad1 SID helix (fig. 7A and B). Even more 







similar PAH2 contact residues with the HBP1 SID Met373, Leu370, Val369, Val367 
and Ala366 residues (fig. 7C). Therefore, this structure suggests a positioning of the 
SID not only N-term to C-term but as well C-term to N-term (fig. 7D). The authors 
conclude that the MXXMMXAA would constitute the minimal core motif for a PAH2 
SID where M is a bulky hydrophobic amino acid. 
4.3.5 Ume6: 
Yeast Ume6 acts as a dual regulator of transcription on URS1 upstream elements of 
early meiotic genes. Repression of meiotic genes by Ume6 protein involves Sin3 and 
RPD3, in contrast to Ume6 transcription activator functions early in sporulation which 
are dependent on an interaction with Ime1 (inducer of meiosis) (10,121-123).  
Kadosh and Struhl showed that a LexA protein fused to the Ume6 residues 508 to 594 
is sufficient to direct Sin3 and Rpd3-dependent repression (10). Furthermore Ume6 
fused to the Gal4 activation domain has repressive effects on a SPO13-LacZ reporter 
which can be suppressed by mutants between residues 523 to 530, within an 
amphipatic Į helix (table 1) (124). In conclusion, Ume6 contains an internal SID, 
which is critical for the regulation of yeast genes expressed early in the meiotic 
transcriptional program. 
4.3.6 Pf1 and the two SIDs: 
Pf1 (PHD factor one) is a protein of 77 kDa which contains two plant homeodomains 
(PHD) zinc finger but apparently lacks the ability to bind DNA. Pf1 acts as an 
intermediate between two co-repressors Sin3 and Groucho/TLE, which are both 
reported to associate with HDAC1 (125,126). Pf1 is an exceptional Sin3 interactor as 
it is able to interact with both the PAH1 and PAH2 domain. The PAH2 SID is a well 
defined small region between residue 208 and 220, whereas the PAH1 SID is defined 
as a large region between residue 300 and 450 (table. 1). The PAH2 SID of Pf1 
contains the sequence LLIAA that is highly similar to the LLEAA sequence present in 
the SIDs of Mad family members, and may explain the nanomolar affinity range of 
this PAH2 interactor in comparison to the micromolar affinity of HBP1 or Sp1-like 
members SIDs which have a poor homology to Pf1 and Mad.  
4.4 PAH1 interacting proteins: 
Remarkably, the PAH2 domain of Sin3 is interacting with many proteins whereas 
only a few proteins have been described to interact with PAH1. In yeast only Opi1 a 
negative regulator of phopholipid biosynthesis was shown to interact at the PAH1 
domain of ySin3. Opi is a yeast transcriptional repressor containing basic leucine 
zipper motifs. Opi1 binds to ICRE’s (inositol/choline responsive element) located in 
genes regulated by inositol and choline such as INO1, CHO1/PSS1, FAS1, FAS2,
ACC1/FAS3 and ACS2. An excess of inositol and choline stimulates repression 
whereas limiting amount causes derepression allowing Ino2 to heterodimerize with 
ino4 to bind ICRE and to mediate transcriptional activation. In a yeast two hybrid, 
Opi1 binds to ySin3 and more specifically to PAH1 upon excess of inositol and 
choline (127). The SID (Sin3 interacting domain) in Opi1 that is required for this 
Chapter 1 
24
interaction has been mapped between residues 45 to 106 and is predicted to adopt an 
amphipatic helix structure. A mutant strain of Sin3 but not of Rpd3 leads to a loss of 
repression of ICRE driven reporter gene suggesting the existence of an Rpd3 
independent repression mechanism. In conclusion, the PAH1 and PAH2 domains of 
Sin3 are both suggested to interact with amphipatic helices SIDs. 
4.5 Crosstalk between co-repressors involving Sin3: 
Sin3 and MeCP2: 
Methylation of CpG dinucleotides is an epigenetic modification widely present in the 
vertebrate genome and plays an important role in X-chromosome inactivation, 
imprinting phenomena and carcinogenesis. MeCP2 belongs to the family of MBD 
(methyl-CpG-binding domain) protein and is involved in transcriptional repression. 
Remarkably, Sin3a and MeCP2 co-fractionate in conventional purification from 
Xenopus extracts and the TRD (transcription repression domain) of MeCP2 has been 
found to be associated with mSin3a, HDAC1 and HDAC2 in GST pulldown assay 
(128,129). The Sin3 region involved in this interaction covers a region including the 
HID between PAH3 and PAH4. It was further shown that TSA can relieve repression 
of MeCP2 on methylated DNA. Therefore there is a relationship between DNA 
methylation-dependent transcriptional silencing and histone deacetylation. 
Sin3, PLZF, PML-RARD and Leukemia: 
Sin3 was also shown to play a role in acute promyelocytic leukemia (APL) with the 
protein PLZF and a structurally similar transcriptional repressor BCL-6 as well as in 
promyelocytic leukemia with PML. PLZF is associated with translocations t(11;17) in 
APL while BCL-6 is associated with translocations in human large cells or follicular 
lymphomas. Both proteins contain an N-term “POZ” motif and a cluster of C2-H2 
“zinc fingers” and are known to function as transcriptional repressors. Interaction 
between mSin3a, mSin3b, HDAC1 and PLZF or BCL6 were shown by GST pulldown 
assays and confirmed by transfection and co-immunoprecipitation (130-132). 
Furthermore PLZF exhibits repression activity in reporter assays in a TSA sensitive 
manner. Interestingly this function is impaired in the presence of the translocation 
product PLZF-RARD which is known to block cell differentiation. Similarly PML 
and the APL transforming protein PML-RARD have been shown to interact with 
mSin3a, HDAC1, N-CoR and c-Ski (133).
4.6 The Sin3 scaffold and its many associated enzymatic activities: 
Sin3 appears to be associated only with histone deacetylase activity, but also other 
activities may participate in repression of transcription. Using stably expressing cell 
line containing flag tagged hBrm1 or hBrg1, mSin3a and p33ING1b could be 
identified (134). p33ING1b is a growth regulator in the p53 pathway that associates 
with Sin3 via direct interaction with SAP30 (135). Interestingly, chromatin 
remodeling and histone deacetylase activity were already shown to be included in 
another class I HDAC containing complex Mi-2/NuRD (nucleosome remodeling), 
thereby suggesting a requirement of both activities in transcriptional repression.
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Glycosylation constitutes another way to enzymatically modify proteins and to 
regulate their activities. O-Glc-NAc is a post-translational modification added on 
serine or threonine amino acid residue by an enzyme named O-Glc-NAc transferase 
(OGT). OGT was shown to interact with the PAH4 domain of mSin3a, which is 
dependent on the presence of TPR domains in OGT. OGT can mediate repression in 
reporter assays and catalyze O-glycosylation of mSin3a and HDAC in transfection 
assays. Remarkably, O-Glc-NAc moieties were also shown to be present on PolII as 
well and correlate with a block in transcriptional elongation (136). Thus, a mechanism 
which includes blocking of PolII by OGT and histone decatylation by Sin3/HDAC 
may act synergistically in transcriptional repression. 
Methylation of histones is yet another way to trigger regulation of transcription. One 
methyltransferase termed ESET (ERG-associated protein with SET domain, a 
suppressor of variegation-enhancer of Zeste and Thrithorax) was shown to co-
precipitate in a transfection experiment with mSin3a, mSin3b and HDAC1/2. ESET 
contains a N-term tudor domain mediating the interaction with Sin3. ESET can 
convert the euchromatic mark dimethyl-H3-K9 into the heterochromatic mark 
trimethyl-H3-K9. Therefore Sin3/ HDAC and ESET histone methyl transferase 
activity may cooperate in transcriptional repression (137,138). 
4.6 Sin3 and cell cycle: 
The Sin3 complex also plays an essential role in the regulation of the cell cycle 
through association with Rb binding protein RBP1 or pocket binding protein p107 and 
p130. Interestingly, RBP1 has been purified from HeLa nuclear extract as a core 
subunit of the mSin3a complex by conventional chromatography (139,140). RBP1 
can recruit the mSin3a/mSin3b/HDAC complex to the pocket of Rb family members 
in vitro. Rb family members repress transcription of E2F family of transcription 
factors essential for DNA synthesis and cell cycle progression. 
Using chromatin immunoprecipitation at different phases in the cell cycle Dynlacht 
lab showed that HDAC1 and mSin3b are recruited to E2F promoters in quiescent cells 
but dissociate in mid-G1 and S-Phase correlating with gene activation. Remarkably 
using pocket binding protein p107 and p130 deficient primary cells they showed that 
mSin3b and HDAC association with E2F promoters are lost while no effect was 
observed with pRB deficent cells. A colocalization of RBP1 and pocket binding 
p107/p130 on E2F promoters has not been observed so far, possibly due to the 
technical limitation of RBP1 antibodies in chromatin immunoprecipitation. Therefore 
RBP1 independent association of Sin3b on E2F promoters remains questionable. In 
conclusion, Sin3 and HDAC play an essential role in maintaining the repressed state 
of E2F genes. 
5. The N-CoR and SMRT complex: 
Nuclear receptor co-repressor (N-CoR) and silencing mediator of retinoic acid and 
thyroid hormone receptor (SMRT) were originally identified as associated with  
unliganded nuclear hormone receptors (141,142). The unliganded form of nuclear 
hormone receptors such as thyroid hormone receptor T3R or retinoic acid receptor 
RAR are correlated with repression of transcription while the hormone bound forms  
are correlated with transcription activation. The repression mechanism of nuclear 
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hormone receptors was partly elucidated when N-CoR and SMRT were shown to 
associate with Sin3 and HDAC1 (143). Biochemical purification of the N-CoR or 
SMRT complex revealed however, that depending on the purification strategy 
employed, different HDACs are associated. A sub-stoichiometric part of the N-CoR 
complex was originally found associated with mSin3a, mSin3b, HDAC1 and HDAC2 
while the majority of N-CoR was later found to be associated with SMRT, HDAC3, 
Kaiso, transducin beta like protein 1 (TBL-1) and TBL1R (84,89,144-147). Therefore 
Sin3/HDAC complex subunits are not core-components of the N-CoR/SMRT 
complex.  
Interestingly TBL1 and TBL1R that are part of the N-CoR/SMRT complex contain 
tandem WD-40 repeats reminiscent of the histone binding protein RbAp46 and 
RbAp48 that are part of Mi-2/NuRD and Sin3 complex. In view of the finding that 
TBL1 and TBL1R can interact with core histones, we can suggest an important role 
for these WD40 repeats proteins in the recruitment of the N-CoR/SMRT complex to 
chromatin.  
6. The Mi-2/NuRD(nucleosome remodeling  and deacetylation) complex: 
6.1 The Core Subunits: 
The Mi-2/NuRD complex was purified in 1998 by several labs and contains the same 
catalytic HDAC1, HDAC2, RbAp46, RbAp48 core proteins which are also found in 
the Sin3 complex. Other core subunits include Mi-2D, Mi-2E, p66D, p66E and MTA2 
(148-150). Mi-2/NuRD is the first reported class I HDAC containing complex 
combining two functions on chromatin: nucleosome remodeling and histone 
deacetylation. Mi-2 originally reported as an autoantigen in the human tissue disease 
dermatomyositis is encoded by two genes Mi-2D and Mi-2E. Mi-2 proteins have a 
chromodomain, two PHD zinc fingers, and a SWI2/SNF2-type helicase/ATPase 
domain which provides chromatin remodeling activity (151,152).
The functional role of p66D and p66E in human is still an open question. It was 
reported that the methyl CpG binding proteins MBD2b and MBD3 directly interacts 
with p66D an p66E in vitro suggesting that the role for these protein in the NuRD 
complex is to recruit MBD proteins (153). In Drosophila, absence of p66 is linked to 
developmental defects during metamorphosis, and overexpression of p66 can repress 
Wnt target reporter genes (154).
MTA2 contains putative zinc fingers and leucine zipper domains and was the first 
reported MTA associated with NuRD. A few years later many MTA members were 
described to interact with NuRD including MTA1, MTA3 and MTA3L (155). The 
different MTA’s contains conserved domains which include the BAH (Bromo 
adjacent homology), ELM (Egl-27 MTA1), SANT and GATA domains. The 
functions of these domains are still unknown.  
MTA1 (Metastasis associated protein 1) was originally identified as being 
overexpressed in metastatic carcinomas, while egl-27 an homolog of MTA1 in 
c.elegans is associated with embryonic patterning (156,157). In human breast cancer 
cells, MTA1 was reported to interact with ER and ER target genes in contrast to 
MTA1s a splice variant of MTA1 lacking nuclear localization signal. MTA1s is 
reported to repress ER transactivation function by sequestrating ER to the cytoplasm 
leading to hyperactivation of the MAPK pathway (158-161).
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MTA2 has been reported to interact with p53. The association of HDAC, MTA2 and 
p53 induces deacetylation of p53, repression of p53 dependent transcriptional 
activation and notably, it modulates p53-mediated cell growth arrest and apoptosis 
(162). Overexpression of MTA2 can be observed in cervical cancer tissue, suggesting
a role for MTA2 in tumor progression.
MTA3 and MTA3L as described by Fujita and colleagues are linked to the ER 
pathway in breast cancer cells like MTA1. MTA3 upregulation is linked to decreased 
Snail expression and increased E-Cadherin level (163). The increase in E-cadherin 
levels restores cell-to-cell junctions and prevents epithelial-to-mesenchymal (EMT)
transition. EMT is a major phenotypic changes occurring in breast cancer metastasis. 
Therefore these results hint to a complex role for MTA3 in modifying ER functions in 
breast cancer cells. Importantly, it was also showed absence of interaction between 
MTA3 and MTA2 or MTA3 and MTA1 suggesting that MTA3 is exclusive in the mi-
2/NuRD complex. Therefore MTA3 may constitute a molecular marker for distinct 
subsets of Mi-2/NuRD complexes. 
6.2 Transcription factors associated with the NuRD complex: 
Targeting of the NuRD complex to chromatin is achieved through association with 
different transcription factors. Ikaros and Aiolos are NuRD associated zinc finger 
DNA binding proteins, essential for commitment of early hematopoietic progenitors 
to the B and T lymphoid lineages. In their absence, mice are immunodeficient and 
display B- and T-cell lymphomas (164,165). Interestingly upon T cell activation, 
Ikaros and Aiolos colocalize with Mi-2 in toroidal structures and recruit NuRD to 
heterochromatic regions, in contrast to Ikaros deficient cells which fail to localize Mi-
2 in toroidal structures, suggesting that NuRD is targeted to those heterochromatic 
regions by Ikaros. Interestingly, Ikaros can also associate with Brg1 based Swi-Snf 
chromatin remodeling complex and is recruited to target genes important for lineage 
commitment and differentiation of T-cell. The association of Ikaros and Brg1 based 
Swi-Snf chromatin remodeling complex at early lineage stages may provide 
accessibility to these target genes and transcription activation. A hypothetical model 
suggests that at later stages of differentiation, repression of these genes may be 
modulated by the Ikaros–Mi-2/NuRD complex.  
More links between B-cell lineage and NuRD have been reported through the 
transcriptional repressor Bcl-6 which regulates cell fate during B-lymphocyte 
differentiation and can be associated with MTA3, and consequently the NuRD 
complex to confer repression to Bcl-6 target genes. (166). An RNAi experiment 
knocking down MTA3 impairs this repression and alters the characteristic 
transcriptional program of a B-lymphocyte. Furthermore, the exogenous expression of 
Bcl-6 in a plasma cell line leads to reprogramming of the cell fate toward that of a B 
lymphocyte in an MTA3-dependent manner. 
In Drosophila, polycomb group proteins play a key role in development by 
maintaining the repressed state of Hox genes. Polycomb proteins are associated with 
heterochromatic regions. One polycomb protein, Hunchback, is a sequence-specific 
DNA binding protein involved in the repression of Hox genes. Yeast two hybrid 
experiments showed that dMi-2 was an interacting partner of hunchback (167). 
Remarkably, a dMi-2 and hunchback double mutant showed a relief of repression on 
the Hox gene Ubx suggesting a functional link between NuRD and hunchback on Hox 
genes. In Drosophila dMi2 associates also with dDREF (DNA replication related 
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elements). dDREF is a protein involved in regulating DNA replication as well as 
boundary formation, and consequently, the Mi-2/dDREF complex inhibits the 
transactivation of dDREF target genes (168).
Recently, GATA-1, a protein essential for differentiation of erythroid cells was 
reported to associate with the NuRD complex using a biotinylation tagging/proteomic 
approach (169). GATA-1 can function both as a repressor and as an activator. NuRD 
is recruited by GATA-1 and the protein FOG-1 to silence hematopoeitic genes in 
erythroid cells. Futhermore GATA-1 repression is relieved, when a mutant of FOG-1 
that does not associate with NuRD, is expressed in erythroid cells (170). 
6.3 NuRD and Methyl CpG binding protein: 
DNA methylation in vertebrate animals is a major regulation process including 
genome defense, X-chromosome inactivation, developmental gene regulation and 
genomic imprinting. DNA methylation pattern are established during embryogenesis 
via a family of DNA methyl transferase and occurs on cytosine in CpG rich regions. 
Methylated CpG islands are generally accepted to be associated with repression. 
Nuclear factors such as MBD1, 2, 3, 4, MeCP2 and Kaiso bind to methylated CpG 
islands. MBD2 and MBD3 have been reported to associate with Mi-2/NuRD in 
human, frogs and flies (171-173). MBD2 contains a N-term region (1-140) rich in 
arginine-glycine repeats and the region (140-400) which displays 70% identity with 
MBD3 (174). A potential splice variant named MBD2b lacks the N-terminal 140 
amino acid suggesting different properties between MBD2a and MBD2b (fig. 8).
Figure 8. scheme depicting primary structure of the MBD2 and MBD3 isoforms. MBD domain, RG 
rich and E domains are indicated. 
MBD3 is a protein of 30 kD highly similar to MBD2 and contains an intact MBD 
domain in contrast to the splice variant MBD3ǻ which contains a truncated MBD 
domain (174). Whereas MBD2 can bind to methylated DNA in vivo, human MBD3 
only displays poor affinity in vitro. Xenopus laevis xMBD3 binds methylated DNA in 
contrast to mammalian hMBD3. The presence of two amino acids in the MBD 
domain of xMBD3 which are absent from the MBD domain of hMBD3 may explain 
the higher affinity of xMBD3 for methylated DNA.  
Interestingly, a knock-out of MBD3 in mice results, in embryonic lethality whereas 
MBD2 knock-out mice are viable and only display subtle behavioral defects and 
protection against intestinal tumorigenesis, suggesting therefore different functions 
for MBD2 and MBD3 (175). 
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7. Outline of this thesis: 
An extensive body of evidence emphasizes the important role of Sin3 and Mi-
2/NuRD in regulating transcription. However, structural functional analysis of co-
repressor molecules is so far limited but essential to understand the molecular 
mechanism of these complexes. The main aim of this thesis was to investigate the 
molecular specificity of the PAH1 and the PAH2 domain of mSin3b and to purify co-
repressor complex using TAP tagging to provide further insights into the function and 
mechanism of class I HDAC containing complex.  
Chapter 2 is a perspective describing high throughput technology including tandem 
affinity purification (TAP tagging), proteomics, chromatin 
immunoprecipitation(ChIP) and ChIP-on-Chip and how these techniques can be 
combined together.  In Chapter 3 we provide a molecular basis for the recruitment of 
Sin3 by the transcription factor Mad1. We develop a gain- and loss-of-function 
approach to decipher the amino acids that are critical for the interaction between the 
SID of Mad1 and the PAH2 domain of mSin3b.  In chapter 4, we extend our 
observations by identifying SID peptide motifs differentially binding to the PAH1 and 
the PAH2 domain. In addition we purify the mSin3b complex using TAP tagging and 
reveal a novel PAH2 associated protein neural retina leucine zipper. In Chapter 5 we 
analyze the complex composition of the MBD2 and MBD3 proteins using TAP 
tagging. We found distinct MBD2/NuRD and MBD3/NuRD complexes suggesting 
that MBD2 and MBD3 are mutually exclusive. Furthermore, we co-purify the 
arginine methyltransferase PRMT5 specifically with the MBD2 complex, suggesting 
the involvement of a new enzymatic activity in Mi-2/NuRD function. In chapter 6 the 
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Abstract 
Despite the availability of several completely sequenced genomes, we are still, for the 
most part, ignorant about how genes interact and regulate each other within a given 
cell type to specify identity, function, and cellular memory. A realistic model of 
cellular regulation based on current knowledge points to multiple interacting networks 
operating at the epigenetic, transcriptional, translational, and posttranslational levels, 
with feedback between the various levels. Protein–protein and protein–DNA 
interactions help define which genes may be activated in a particular cell, and 
determine whether external cues cause activation or repression. New technologies-
proteomics using mass spectrometry, high-density DNA or oligonucleotide 
microarrays (chips), and chromatin immunoprecipitation (ChIP)-provide new and 
exciting tools for deciphering the pathways and proteins controlling gene expression. 




Our knowledge about the human genome has increased exponentially over the past 50 
years, following the description of the structure of DNA by Watson and Crick (1). 
The 4 bases forming the structure have been identified, and the genetic code has been 
deciphered.  Basic mechanisms for transcription and translation have been described.  
Techniques have been developed to sequence both individual genes and the genome 
as a whole. The sequence information has, in turn, helped to identify open reading 
frames and intron/exon boundaries.  However, the process by which expression of 
individual genes or groups of genes actually occurs in different cell types is not as 
clear.
In a human cell, approximately 2m of DNA are packed into a nucleus as a 
superstructure called chromatin. Microscopically, dense and light staining nuclear 
regions can be distinguished and have been classically defined as heterochromatin and 
euchromatin. Although these are cytologic terms, heterochromatin and euchromatin 
are generally regarded as closed and open, or transcriptionally inactive and active, 
respectively. Chromatin structure not only serves to store the genetic material but also 
has a very important functional role in regulating gene expression. Although a wide 
variety of DNA-associated proteins are present, it is the nucleosome—an octamer of 4 
different histones around which the DNA is wrapped—that represents the basic repeat 
unit within the chromatin. This packaging of the DNA creates a barrier for reading 
and interpreting the stored DNA-sequence information. Access to this information is 
controlled at the level of the histones: post-translational modifications especially at 
the histone N-termini direct transcription processes. Different combinations of 
phosphorylation, methylation, acetylation, and ubiquitination marks determine 
whether nucleosomes, for example, will be remodeled to establish a transcription-
permissive chromatin structure. As such, the pattern of modifications within the 
chromatin serves as a “barcode” that provides information about the transcriptional 
state of a gene. This is known as the “histone code” theory (2). Histone-modifying 
enzymes such as histone acetyltransferases (HATs), histone deacetylases (HDACs), 
and histone methyltransferases (HMTs) “write” this barcode, whereas other protein 
complexes “read” and interpret the code. Apart from the modifications present on 
histones, the DNA itself is also subject to modification. DNA is subjected to 
methylation of cytosine bases within CpG dinucleotides.  
The information that is encoded by the palette of modifications is regarded as 
“epigenetic,” because it provides a heritable source of information that is passed on 
independently of DNA sequence. Gene expression is therefore regulated not only by 
DNA sequence, but also by epigenetic determinants, histone-modifying proteins, and 
proteins that interpret these marks. Such proteins are typically constituents of multi-
subunit protein complexes. As such, protein–protein interaction networks determine 
which genes may be activated in a particular cell as well as whether a molecule will 
act as an agonist, an antagonist, or a neutral agent in a given cell pathway. This 
additional level of complexity allows the existence of multiple cell type–specific 
“epigenomes” within a single organism.  
The influence of the epigenetic state on gene expression is very apparent in the 
process of X inactivation, which ensures that only 1 of the 2 X chromosomes in the 
female cell is transcriptionally active. This is accomplished through epigenetic 
modifications and results in silencing of 1 of the 2 X chromosomes (fig. 1). Analysis 
of the human Xi and Xa, mostly by ourselves and others, revealed that the 2 alleles of 
a given X-linked gene display different patterns of histone modifications (3-5). Thus, 
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although these 2 X chromosomes share the same DNA sequence, it is their epigenetic 
state that determines whether and how DNA-encoded sequence information is used. 
Although genomic sequences thus serve as blueprints for the biology of a cell, DNA 
sequence information alone does not provide sufficient information to decipher the 
mechanisms that underlie processes such as cell specialization and reprogramming of 
cancer cells. Clearly, large-scale and genomewide analysis of epigenetic patterns is 
necessary to understand these processes. New technologies—including proteomics, 
microarrays, chromatin immunoprecipitation (ChIP), and a combination of these 
techniques—provide unique and exciting tools to investigate chromatin structure and 
the proteins controlling gene expression through chromatin structure. In this review 
we will describe recent progress and discuss how these novel technological advances 
can be used to gain insight into the complex mechanisms underlying regulation of 
gene expression and the targeted development of therapeutic agents. 
Figure 1. Influence of the epigenetic state on gene expression. X chromosome inactivation is the 
dosage control mechanism by which 1 of the 2 X-chromosomes in mammalian female XX cells is 
subject to complete silencing. Establishment of the inactive state is characterized by epigenetic 
alterations such as posttranslational modifications of histone tails. As a result, a different histone code 
is present at the 2 alleles of a given X-linked locus.  
Analysis of the transcriptome  
Within the past decade, technological advances have enabled large-scale gene 
expression analysis or “expression profiling.” These emerging technologies have 
proved to be highly useful in the elucidation of novel regulatory pathways associated 
with a variety of diseases. The availability of such expertise is crucial to correlate 
gene expression status with associated epigenetic patterns. 
Fluctuations of mRNA levels in a cell are mostly caused by changes in the 
transcriptional rate of genes, but they also involve posttranscriptional events. The 
strategy for analyzing the abundance of mRNAs on a large scale—expression
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profiling using DNA microarrays—has become a widely used technique. In short, 
RNA is converted to cDNA, labeled with Cy3 or Cy5 fluorophores, and hybridized to 
a DNA microarray or “gene chip.” The current generation of DNA microarrays 
consists of a glass slide containing tens of thousands of DNA target molecules of 
known identity. Labeled cDNAs that specifically hybridize with their complementary 
target DNA molecule are retained on the microarray and can be quantitatively 
measured. Typically, in a single experiment one compares pools of reference cDNA 
labeled with Cy3 with a cDNA preparation labeled with Cy5 from cells triggered by 
an external stimulus such as ligand. Both pools are hybridized on the microarray, and 
the intensity of each fluorophore is measured at 2 different wavelengths. The ratio 
value of the 2 intensities is determined to identify upregulated or downregulated 
genes.  
Gene expression profiling using DNA microarrays and other variants of the 
microarray technique has been successfully used to elucidate changes occurring 
during tumor development and progression. For example, oligoarrays have been used 
in clinical research to identify upregulation of cytokine genes in biopsies from human 
renal allografts undergoing acute rejection (6). Oligonucleotide microarray analysis of 
6416 genes and expressed sequence tags was used to demonstrate the effects of the 
proto-oncogene myc on cell growth, cell cycle progression, adhesion, and cytoskeletal 
organization (7). Use of cDNA microarray analysis combined with gene-specific 
analysis showed upregulation of DD3, a gene that is specific to prostate cancer, and 
downregulation of insulin like growth factor (IGF) binding protein–3 (8,9). 
Microarray analysis also showed that p300/CREB-binding protein (CBP)–associated 
factor, a coactivator of the tumor suppressor p53 gene, was induced by p53 in breast 
tumor cell lines (10). 
An alternative approach to expression profiling involves the use of high-density 
oligoarrays spanning entire chromosomes (so-called tile path arrays). In one 
application of this type of array, researchers use microarrays containing 
oligonucleotides placed every 50 bp, allowing high-resolution analysis of 
transcription of an entire chromosome or the whole genome. In an in-depth analysis of 
human chromosomes 21 and 22, this technique identified 126 novel transcripts (11). 
In addition, the authors identified a large number of novel noncoding RNA transcripts 
with yet unknown function, showing the power of unbiased approaches.
Analysis of the proteome 
Proteomic analysis is challenged by the entire set of proteins expressed by a cell. The 
human genome contains more than 25,000 genes. Alternative splicing of mRNA, 
proteolytic cleavage as well as posttranslational modifications of proteins increases 
the complexity of the human proteome up to about 100 million different polypeptide 
chains. In “classic” proteome analysis approaches, one makes use of 2-dimensional 
gel electrophoresis followed by isolation and characterization of individual protein 
spots by mass spectrometric analysis. This approach is labor intensive and time 
consuming, hampering rapid and complete analysis of the proteome. The time 
required for comprehensive proteomic analyses has recently decreased significantly 
by novel developments improving methods as well as instruments. These include 
separation of complex protein mixtures on microcapillary liquid chromatography, 
electrospray ionization (ESI), tandem mass-spectrometry (MS/MS), Fourier transform 
ion cyclotron resonance MS (FT-MS) and highly improved database search 
algorithms. The high accuracy and sensitivity now allow the unequivocal 
identification of peptides, including their posttranslational modifications at the 
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femtomole level. Using this approach, we have analyzed the proteomes of asexual 
blood stages, gametocytes, and gametes of the human malaria parasite Plasmodium 
falciparum (12). By separating complex peptide sample mixtures on a reverse-phase 
column and direct on-line injection into the mass spectrometer, we identified 1289 
proteins.
Due to the increased sensitivity of mass spectrometry, stable isotope labeling with 
amino acids in cell culture (SILAC) has provided another technical advance that holds 
great promise for large-scale quantitative proteomic analysis.  In this method, 
replacement of amino acids by “heavy” isotope–containing amino acids, such as 
13[C6]-Arg, is achieved by simply culturing a cell population in medium 
supplemented with the “heavy” amino acid. Labeled and unlabeled cells can be 
treated with different stimuli, such as agonist or antagonist, and are subsequently 
combined before further purification (13,14). Because of the presence of a light and 
heavy isotope, a qualitative and quantitative comparison of the peptide complement in 
the 2 cultures through mass spectrometric analyses has become feasible. The ratio of 
peak heights between “heavy” and “light” peptides correlates with the presence or 
absence of a protein as a consequence of drug treatment. Using this SILAC approach, 
de Hoog and colleagues identified new cell adhesion components by “simply” 
comparing labeled attached cells with unlabeled detached cells. The results showed 
the unexpected involvement of RNA and RNA binding proteins in contacts between 
cells and the matrix. As modulation of cell adhesion is a prerequisite for tumor 
metastasis, these new results help to pinpoint novel targets for drug development. The 
SILAC approach also has been used in the analysis of microsomal fractions of highly 
metastatic prostate tumors and has led to the identification of proteins that were 
elevated and reduced in metastasizing cells when compared with nonmetastasizing 
cells (15). 
Recently, high-throughput experimental approaches have been established in yeast 
and other organisms to gain insights into the network and composition of protein 
complexes inside a cell. These approaches involve fusion of epitopes, for which a 
high-affinity antibody is available, to a protein of interest, a procedure termed 
tagging. Through homologous recombination in yeast, the wild-type gene is replaced 
with its tagged version. The tagged protein of interest is subsequently purified along 
with putative interacting partners via a technique called tandem affinity purification 
(TAP) (16). The purified protein complex can be visualized by silver staining and 
analyzed by mass spectrometry or directly analyzed by liquid chromatograph (LC)–
MS/MS. Newly identified subunits of a particular complex are validated by tagging 
these novel subunits and repeating the purification and analysis. Using this procedure,
one can “walk” from one protein complex to the next and visualize the “interactome” 
to provide a functional context of a certain group of proteins. A combination of TAP 
and mass spectrometry analyses of the Saccharomyces cerevisiae (baker’s yeast) 
proteome led to the identification of 232 distinct multiprotein complexes and the 
assignment of possible functions to these complexes (17).  
TAP approaches have been applied successfully to mammalian cells using a retroviral 
gene delivery or stable inducible system, and were applied in our lab for purifying 
protein complexes involved in gene silencing (18-20). Purification of a TAP-tagged 
MBD3 (methyl CpG binding protein) resulted in purification of the Mi-2 complex, a 
complex containing nucleosome remodeling as well as histone deacetylase activity 
(fig. 2). MBD3 is known to be a part of the Mi-2 complex. The purified MBD3 
complex displayed potent histone deacetylase activity (data not shown) demonstrating 
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that the retrovirally transduced MBD3 protein assembles into a functional complex 
that can be purified.
Figure 2. A stable cell line expressing a tagged MBD3 protein was subjected to TAP-tag purification. 
The purified complex was loaded on a 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE) gel, after which proteins were visualized using silver staining 
Analysis of protein-DNA interactions in vivo 
The recent development that enabled the study of protein-DNA interactions in vivo is 
ChIP. Since its introduction some 10 years ago for the analysis of polycomb-group 
proteins binding to the Drosophila BX-C locus, it has become a widely used technique 
(21). In short, the addition of formaldehyde to living cultured cells introduces 
covalent cross-links between proteins interacting with DNA, RNA, or other proteins 
resulting in “freezing” of protein–protein and protein–DNA interactions in vivo. 
Fragmentation of the chromatin and immunoprecipitation of the protein-DNA 
complexes using a specific antiserum facilitates purification of a particular protein 
and co-purification of cross-linked DNA fragments (fig. 3). In a “conventional” ChIP 
experiment, the presence of particular DNA sequences in the precipitate is 
subsequently analyzed using quantitative polymerase chain reaction (PCR). 
Amplification of the target site (A) in parallel with an unrelated sequence (B) reveals 
whether the immunoprecipitated protein was bound to its presumed target site in vivo. 
Thus, the association of a protein with its binding site in vivo can be measured by 
ChIP, provided that antibodies against the protein are available. ChIP has been used to 
investigate the in vivo binding sites of a multitude of transcription factors including 
nuclear hormone receptors (RXR, v-ErbA, ER, PPARȖ), myc, and the p53 family (22-
29). In addition, the availability of antisera against specific histone modifications or 
methylated DNA allows one to study the distribution of epigenetic modifications on 
particular loci. ChIP can also be used to analyze cell-type and ligand-specific cofactor 
recruitment. Experiments conducted with estrogen receptor (ER)–mediated activation 
revealed that multiple chromatin-modifying complexes are sequentially and 
independently recruited (30,31). In addition, repression mechanisms induced by 
tamoxifen-loaded ER could be delineated (32). Such studies, when performed on a 
global scale, provide insight into the mechanisms that dictate cellular responses to 
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hormone and could provide a rationale for the development of drugs that target 
specific pathways.  
Figure 3. Principle of chromatin-immunoprecipitation (ChIP). A DNA-binding protein X that in vivo 
binds to site A but not site B (1) will be covalently cross-linked to site A by the addition of 
formaldehyde to the growth medium (2). Cells are subsequently lysed and sonicated to generate 
chromatin fragments with an average length of 0.5 to 1 kb. Immunoprecipitation using an antiserum 
against protein X will result in the specific enrichment of protein X cross-linked to site A (3). Site B 
DNA fragments are removed by subsequent washing steps. After heat-reversion of the cross-links, the 
immunoprecipitated DNA fragments are purified (4) and analyzed using quantitative PCR (5). 
ChIP-on-chip in analysis of protein–protein and protein–DNA interactions 
ChIP approaches provide valuable information about the involvement and 
chronology of transcription factor and cofactor recruitment during activation or 
repression of a locus.  Furthermore, ChIP provides a means to accurately determine 
the factor composition and epigenetic status of a gene and its regulatory regions 
(33,34). In a few cases, complete loci or large chromosomal regions have been 
investigated, but application of the gene-by-gene ChIP approaches to large sets of 
genes or even the whole genome is cumbersome and labor intensive (35-37). 
Furthermore, without prior knowledge such experiments would be very costly fishing 
expeditions. To facilitate large-scale analyses, ChIP has recently been combined with 
microarray technology (36). In such so-called ChIP-on-chip experiments, DNA 
obtained by conventional ChIP is amplified, labeled, and hybridized on a DNA 
microarray. This allows the identification of target sites for a certain protein on a 
genomewide level. ChIP-on-chip was initially applied to yeast, where novel target 
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sites for Gal4 and Ste12 were identified through the use of a microarray that contained 
all intergenic sequences. Such genomewide studies are exceedingly more complex 
when dealing with higher eukaryotes. Due to their genome size, the presence of 
repetitive sequences and the widespread distribution of regulatory elements, the 
development of suitable microarrays for ChIP-on-chip is a demanding task. The 
several types of DNA arrays currently in use are as follows: (1) tailored/designed 
target gene arrays, consisting of preselected PCR-amplified genomic sequences; (2) 
CpG-island arrays, generated by cloning of GC-rich DNA fragments purified from the 
human genome; (3) oligo tile path arrays spanning whole chromosomes or even the 
whole genome; and (4) ChIP-cloning arrays consisting of DNA fragments obtained by 
cloning precipitated ChIP DNA. Although CpG-island microarrays have the limitation 
of being restricted to high-GC–containing DNA sequences, they have successfully 
been used for the identification of novel targets for E2F, polycomb group (PcG) 
complexes, and MBD proteins, as well as  histone H3K9 methylation (38-42). A 
recent and more unbiased ChIP-on-chip study made use of oligonucleotide tiling 
arrays completely covering human chromosome 21 and 22. This resulted in the 
identification of c-Myc, p53 and Sp1 target sites in a chromosomewide manner (42). 
An attractive alternative to generate microarrays is ChIP cloning. In this approach, 
DNA, which is brought down in a ChIP, is purified and cloned, yielding a library of 
target sites. Subsequently, the cloned fragments are printed on a microarray. Because 
ChIP cloning does not require preexisting knowledge, a genuine target within the 
genome will be present within the resulting library of DNA fragments. ChIP cloning 
has been applied to E2F and CTCF (43,44). In our laboratory, we have recently 
adopted it for the construction of a TBP-binding site microarray by using a highly 
specific antibody against TBP. Because TBP is a central transcription factor for RNA 
polymerase I and II, as well as RNA polymerase II promoters, we obtained a 
comprehensive library of presumed promoter sequences. In addition to identifying 
novel promoters, this approach has facilitated the analysis of the basal transcription 
factor composition of various promoter classes. Furthermore, the epigenetic signature 
and cofactor recruitment to distinct promoters can now be determined. The 
technology allows determination of the targets as well as the pathways for 
recruitment. The scatter plot in figure 4 displays data obtained from a ChIP-on-chip 
experiment. Two different DNA samples, obtained by ChIP using antibodies against 
serine 5 phosphorylated RNA polymerase II, and anti-BDP1 (a subunit of RNA 
polymerase III initation factor), were hybridized onto the TBP target site microarray. 
Displaying the signal intensities for the 2 ChIP samples (Cy3 and Cy5) in a scatterplot 
reveals 2 distinct populations, one containing polymerase II promoters and one 
containing polymerase III promoters associated with tRNA genes.  
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Figure 4. Chromatin-immunoprecipitation (ChIP)-on-chip analysis using a TBP-target site microarray. 
(A and B) ChIP was performed using antibodies against serine 5 phosphorylated RNA polymerase II or 
anti-BDP1. Obtained samples were hybridized onto the TBP-microarray. Signal intensities were 
compared with TBP ChIP samples in a scatter plot. (C) FLAG-tagged p73 was used for ChIP, after 
which the immunoprecipitated DNA fragments were hybridized onto the TBP microarray. Signal 
intensities were compared with a nonimmunoprecipitated (input) sample in a scatter plot. The circled 
area represents p73 target sites. (D) Some of the identified target genes were validated using 
conventional gene-specific ChIP. 
A similar ChIP-on-chip strategy was used for target-site analysis of p73, a close 
relative of p53 that plays a role in oncogenesis and transformation (fig. 4C).  A stable 
cell line expressing FLAG-tagged p73 was used for ChIP, after which the 
immunoprecipitated DNA fragments were hybridized onto the TBP target site 
microarray.  The circled area in Figure 4C represents p73 target sites. Some of the 
identified target genes were validated using conventional single-gene ChIP (fig. 4D). 
A similar ChIP-cloning approach for p53 using a specialized dedicated array will 
allow genomewide localization of target sites.  
Combining the best of 2 worlds: proteomics and ChIP-on-chip are 
complementary techniques 
Although dedicated microarrays generated by ChIP cloning are valuable tools in 
target- site analysis, they require the availability of a highly specific and “ChIP-
grade” antiserum against the protein of interest. Because such requirements cannot 
always be fulfilled for each protein, TAP-tagging approaches used in MS also can be 
used for ChIP cloning. This involves the generation of a stable cell line expressing 
epitope tags fused to the protein of interest. These cells can now be subjected to ChIP 
or protein complex purifications using antibodies against the tags. We are currently 
screening and selecting such dual-purpose “generic” tags that will allow purification 
of protein complexes as well as ChIP cloning to determine where in the genome the 
factor exerts its function (fig. 5).
Chapter 2
56
Figure 5: Proteomics and ChIP-on-chip are complementary techniques. Applications of a stable 
cell line expressing a tandemly tagged protein of interest are shown.  
When combined, proteomics and ChIP-on-chip may help to decipher pathways and 
gene networks regulated by transcription factors such as nuclear receptors. Subtypes 
and cell-type specificity of nuclear receptors can be determined as well as ligand-
dependent recruitment of factors. Analysis of the composition of corepressors or 
coactivators recruited by the different nuclear hormone receptors by LC-MS/MS can 
be combined with an analysis of DNA target sites using stable cell lines expressing 
generic tagged nuclear receptors. Epigenetic marking, including cell-type specific 
chromatin modifications, DNA methylation, and locus-specific susceptibility to 
activation will soon be within reach and will add a new dimension to targeted drug 
development. 
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Abstract
The Sin3 co-repressor acts as a protein scaffold to recruit transcription factors via its four 
highly homologous PAH domains (Paired Amphipathic Helix). PAH2 has been shown to 
interact strongly with the SID (Sin3 Interacting Domain) of the tumor suppressor Mad. 
This PAH2/Mad complex has been extensively studied by NMR but the molecular 
determinants that dictate the specificity of interaction remained to be elucidated. To 
uncover residues that convey the specificity of interaction between PAH2 and Mad, 
PAH2 residues contacted by the Mad-SID were introduced into the PAH1 domain of 
mSin3b and tested for gain-of-interaction in vivo in a yeast two hybrid setting and further 
confirmed in a cell free system.  This approach led to the identification of PAH2-Phe7 as 
a critical residue. Stabilisation of the interaction between PAH1-Phe7 and the Mad-SID 
was achieved by introducing Val14 and Gln39 into PAH1. Substitution of PAH2 residues 
contacted by the Mad-SID with their respective residues in PAH1 corroborated and 
extended the critical role of Phe7 and the stabilising role of Val14 and Gln39. We 
conclude that Phe7 is the critical determinant and provides the molecular specificity for 




The ordered and specific/selective recruitment of multiprotein complexes with intrinsic 
chromatin remodelling or histone modifying activities to cis-acting DNA elements has 
emerged over the last decade as one of the major mechanisms to regulate transcription and 
cell fate determination (1). A plethora of studies have collectively shown that acetylation of 
specific N-terminal lysine residues of core histone tails by histone acetyl transferases (HATs) 
creates a chromatin state which results in transcriptional activation (2). Removal of the acetyl 
moiety by histone deacetylases (HDACs) restores the compact state of chromatin resulting in 
transcriptional repression. One of the players in this mechanism is the evolutionary highly 
conserved and ubiquitously expressed co-repressor Sin3. Sin3 acts as a scaffold protein in 
many complexes and presumably contributes to repression of transcription by interacting 
with human class 1 histone deacetylases, HDAC1, HDAC2 or the S. cerevisiae homolog 
Rpd3 (3-9). Purification of Sin3 containing complexes has revealed a core complex 
containing HDAC1/2, the pocket binding protein RBP1, Sds3, the histone binding proteins 
RbAp46 and RbAp48, and accessory protein such as SAP30 and SAP130 (9-13).  
A large number of transcription factors have been described to recruit Sin3 to target genes. 
These include: Pf1, TIEG2, Opi1, Mnt, Mad family members and S. cerevisiae Ume6 (6,14-
23). The interaction between Mad and Sin3 is of great interest as it targets deacetylation and 
repression of transcription to genes required for proliferation of cells. Mad belongs to the 
basic helix-loop-helix-leucine zipper protein family and is part of the Myc/Mad/Max 
network. The tumor suppressor Mad and the proto-oncogene Myc independently 
heterodimerize with Max to form complexes capable of targeting the hexanucleotide core 
sequences 5’-CACGTG-3’ enhancer box (E-box) present on specific promoter such as cyclin 
D2, htert and Id2 (24-29). The Myc/Max heterodimer can recruit the TRRAP/GCN5 complex 
containing HAT activity in proliferating cells as opposed to the Mad/Max heterodimer which 
recruits the Sin3 complex triggering deacetylation of histones in differentiation (30-32).
Interactions between Sin3 and transcription factors are mediated by 4 PAH domains within 
the Sin3 protein. Opi1, pf1, N-CoR and the SMRT co-repressor have been described to 
interact with PAH1 (33,34). PAH2 has been reported to interact with Mad family members, 
Mnt, Ume6, as well as with TIEG2 and Pf1. So far, PAH3 has been shown to interact with 
SAP30. Recently glycosylation was linked to transcriptional repression by showing 
interaction between PAH4 and O-GlcNAc transferase (35). A minimal conserved binding 
motif consisting of the N-terminus residue 8-20 of Mad1 was established to interact strongly 
to PAH2 (36). The interaction between the PAH2 domain of Sin3 with the SID of Mad has 
been characterised in detail by NMR. PAH2 folds as a wedged four-helix bundle structure 
that is stabilised upon complex formation with the Mad-SID that adopts an amphipathic D
helix (37,38). Although the four domains have a high degree of homology, they appear to 
interact with distinct subsets of factors. Structural prerequisites of PAH interactors for a 
stable interaction with a PAH domain appear to be D helicity and amphipaticity, but the 
structural studies do not shed light on the role of individual residues in binding and 
specificity.  
Here, to uncover residues that convey the specificity of interaction between PAH2 and Mad, 
PAH2 residues contacted by the Mad-SID were introduced into the PAH1 domain of mSin3b 
and tested for gain of interaction. We report that the insertion of PAH2 specific residue Phe7 
Molecular determinants of the interaction of Mad with the PAH2 domain of mSin3b 
67
in PAH1 conveyed an interaction with the Mad-SID. Stabilisation of Mad-SID interaction 
with PAH1-Phe7 occurred upon extra insertion of Val14 and Gln39. Strikingly, in PAH2, 
Phe7 was further identified as a critical residue. Overall we establish Phe7 as the most 
important molecular determinant of the interaction between PAH2 and Mad. 
Material and Methods 
PAH1/PAH2-Mad-SID binding assay  
The Mad-SID 5-24 fused to the GB1 domain of streprococcal protein G was prepared as 
described earlier (37). GST-PAH1 (amino acids 34-108) and GST-PAH2 (amino acids 148-
252) were expressed and purified as described previously (39). 
GST-PAH1 or PAH2 (10Pg) were incubated with protG-Mad and bound to IgG-Sepharose 
(Pharmacia) in 150 mM NaCl, 20 mM Tris pH 7.6. Beads were washed 3 times with 600 mM 
KCl, O.2 % NP-40 (v/v), 20 mM Tris pH 7.6. GST-PAH1 and GST-PAH2 mutant fusion 
proteins were incubated with protG-Mad in 150 mM NaCl, 0.5 % NP-40 (v/v), 0.01 % SDS, 
5 mM EDTA, 20 mM Tris pH 7.6 and washed 3 times in the same buffer.   Bound proteins 
were eluted with 0.1 M Glycine pH 2.6, separated by SDS gel electrophoresis, and coomassie 
blue stained. 
Cloning and mutagenesis 
Fragment containing the PAH1-PAH2 domain of pvzmsin3b was cloned into pBS-SK-
(stratagene) as a SacII/EcoRI fragment yielding PBS-PAH1-PAH2. Site-directed 
Mutagenesis was performed on PBS-PAH1-PAH2 using QuickChange site directed 
mutagenesis kit (Stratagene) following the manufacturer’s protocol. All mutations were 
confirmed by DNA sequencing   
Wild type or mutated PAH1 fragments of msin3b containing amino acid 25 to 107 were 
generated by PCR with primers pair PAH1F97/PAH1R97m containing respectively SalI and 
NotI restriction sites overhangs. PAH1F97: (5’-
GTGAGGTCGACCGGAGGGCACGAGAAGCTG-3’); PAH1R97m: (5’-
GTCAGTAGCGGCCGCCTTGGGGATATCTATACGGTATCCA-3’) Wild type or mutated 
PAH2 fragments of msin3b comprising amino acid 136-275 were generated by PCR using 
PAH2F97/PAH2R97 primer pair containing SalI and NotI restriction sites. PAH2F97: (5’-
GTGAGGTCGACCATGTCCTACAAGGAGGACAGAG-3’); PAH2R97: (5’-
GTCAGTAGCGGCCGCAGACACAGGGCGCAGGAGTGA-3’). In frame cloning of the 
amplified fragments was performed using SalI/NotI cleaved pCP97 bait vector containing the 
GAL4DNA binding domain (40).  Using primer pair PGEXPAH1F/PGEXPAH1R or 
PGEXPAH2F/PGEXPAH2R containing BamH1 and EcoR1 restriction sites, we generated 
PAH1 and PAH2 PCR fragments. Amplified fragments were fused to GST using 







Mad-SID containing protein sequence V5RMNIQMLLEAADYLERRER24 was generated by 
annealing phosphorylated oligos containing RsrII overhangs. Cloning in frame with GAL4 
activation domain and thioredoxinA was done using RsrII restriction site in the prey vector 
pADTRX (40). All constructs were confirmed by automatic DNA sequencing.   
Yeast two hybrid 
LiAc Transformation were performed on Saccharomyces cerevisiae Y190(clontech) 
according to the Clontech yeast protocols Handbook. Quantitative E-galactosidase assay was 
performed using O-nitrophenyl E-D-galatopyranoside (ONPG) as a substrate. Fresh 
transformants were grown overnight in 5 ml SD-leu-trp selective culture medium. 1.5 ml 
cells were concentrated 5 times in Z buffer (60 mM Na2HPO4, 60 mM NaH2PO4, 10 mM 
KCl, 1 mM MgSO4 pH 7.0). Cells were resuspended in 100 Pl Z buffer and freeze thawed. 
0.7 ml Z buffer with 50mM E-mercaptoethanol and 160 Pl (4mg/ml) ONPG was added to 
initiate the reaction. Incubation at 30qC for 30min-2 hours was performed. Reaction was 
stopped with 0.4ml of 1M Na2CO3. E-galactosidase units were calculated according to the 
formula  E-galactosidase units(Pmol ONPG.min-1)=1000*OD420/(time in min*0.1*5*OD600).
Experiments were repeated at least 3 times in triplicate. 
Results 
Mad Preferentially binds PAH2 in vitro and exclusively in vivo 
The Sin3a and Sin3b co-repressors both contain 4 PAH domains mediating protein-protein 
interactions. Despite significant homology, PAH1, PAH2, PAH3 and PAH4 domains appear 
to associate with distinct proteins. Clustal alignment reveals a significant sequence identity 
between PAH1 and PAH2 domains from yeast to human of about ~45% (fig. 1A). Contact 
residue analyses from the NMR structure of the PAH2 domain of mSin3a or mSin3b with the 
Mad-SID reveals a number of PAH2 specific residues.  Some contact residues are conserved 
between PAH1 and PAH2 whereas others are distinct and may provide specificity to the 
interaction. Interestingly, they are exclusively located in helices 1 and 2 (boxed in figure 1A). 
To assess the ability of PAH1 and PAH2 to interact with the Mad-SID, the domains were 
fused to GST, purified and incubated with immobilized protG-Mad bound to IgG Sepharose 
beads. When ProtG-Mad was in excess, both GST-PAH2 and GST-PAH1 were able to bind 
the Mad-SID (fig. 1B). Incubating equal amount of GST-PAH1 and GST-PAH2 with 
decreasing amounts of protG-Mad, i.e. creating a competitive setting, indicates that Mad-SID 
binds preferentially to PAH2 in vitro.
To ascertain this differential interaction in vivo, we performed yeast two hybrid experiments. 
The PAH1 and PAH2 domains of msin3b were fused to the DNA binding domain of Gal4 
(G4DBD) and used as baits. As a prey, a constrained Mad-SID displayed in the active site 
loop of E. coli thioredoxin (TRX) molecule was used, fused to the Gal4 activation domain 
(G4AD-TRX-Mad). PAH2 expression in combination with Mad resulted in a robust E-
galactosidase level whereas PAH1 yielded background levels (fig. 1C). This activation 
mediated by G4DBD-PAH2 was strictly dependent on the presence of the Mad-SID as TRX 
alone resulted in background levels. Thus, the Mad-SID preferentially interacts with PAH2 in 
vitro and more selectively so in vivo.
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Figure 1. Mad selectivity at the PAH1 and the PAH2 domains in vitro and in vivo. A) Multiple sequence 
alignments of the PAH1 and the PAH2 domains of sin3. Alignment was generated with ClustalW and manually 
improved. Helical regions of the PAH2 domains are indicated with cylinders at the bottom. Residues mutated in 
this study are boxed. (.) Indicates PAH2 residues involved in contacting the Mad-SID, information was 
retrieved from NMR structure of the PAH2 domain of msin3a and msin3b (PDB accession number: 1G1E and 
1E91 respectively). B) In vitro pull down assay suggest a preferential binding of Mad to PAH2. (top left panel:) 
GST-PAH1 and GST-PAH2 bind separately to the Mad. Excess amounts of GST-PAH1 and GST-PAH2 were 
incubated with IgG-Sepharose in the presence or absence of ProtG-Mad-SID(5-24) and washed extensively. 
Bound material was eluted, separated on SDS-PAGE and coomassie blue stained. (top panel) Mad preferentially 
binds to PAH2 upon reducing amounts of Mad. (bottom panel). C) In vivo interaction in a yeast two hybrid 
assay suggests an exclusive interaction of Mad with PAH2. G4DBD-PAH1 or PAH2 were transformed in yeast 
with a prey containing G4AD fused to the thioredoxin A protein (G4AD-TRX). Mad-SID(5-24) was inserted in 
the constrained active site loop of thioredoxin to generate G4AD-TRX-Mad. Quantitative E-galactosidase 






































Exchange of contact residues between PAH2 and PAH1 
The observed selective interaction between Mad and PAH2 in vivo in a yeast two hybrid 
setting suggests that unique residues within PAH2 play a selective role in binding of the 
Mad-SID. We used molecular modeling of PAH1 with WHAT IF (41) and superposition of 
the PAH1 model with the NMR structure of the PAH2 domain of msin3b with the Mad-SID 
to pinpoint potential selective PAH2 residues (fig. 2) that may affect binding of  Mad-SID in 
vivo. This revealed E6, F7, I11, V14, N15, I17, R29, L35, H36 and Q39 as potential selective 
modifiers. Therefore, we performed a systematic mutational analysis replacing the respective 
PAH1 residues with the potentially selective PAH2 residues. Each mutant was then fused to 
the G4DBD and tested in the yeast two hybrid setting. 
Figure 2. PAH1 molecular model derived from homology modeling of the NMR structure of the PAH2 domain 
of msin3b with the Mad-SID(5-24) points to potential PAH2 selective residues. PAH1 residues depicted at the 
interface with the Mad-SID were mutated into the respective PAH2 residues described in the table. The PAH1 
model was generated with WHAT IF and molecular picture was generated with YASARA (42) and POVRAY. 
PAH1 is displayed in blue and Mad-SID(5-24) is displayed in orange. Sidechains of PAH1 residues mutated in 
this study are shown and labeled.
Single amino acid replacement in PAH1 revealed only one mutation, M35L, that yielded 
elevated levels of E-galactosidase expression i.e. 5% of the level obtained with PAH2 and 
Mad (fig. 3A). To identify additional residues, a second cycle of single amino acid 
substitutions was performed this time in the context of M35L. Some combinations such as 
K36H with M35L yielded reduced level whereas others appeared neutral. A significant 
enhancement of the interaction was observed with the double mutant containing V7F (fig. 
3B). Unexpectedly, two hybrid assays performed in the absence of Mad or in the absence of a 
prey showed that PAH1-M35L had gained intrinsic transcriptional activity. On top of this 
intrinsic transcriptional activity displayed by PAH1-M35L, the double mutant PAH1-V7F-
M35L yielded a significantly higher E-galactosidase level that was dependent on the presence 
of the Mad-SID. Apparently the intrinsic activity of PAH1-M35L had elevated the overall 
activity into a measurable range thereby facilitating detection of the V7F effect in the yeast 
two hybrid assays. As observed in fig 3A, the interaction of PAH1-V7F with Mad-SID was 
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Figure 3. Phe7, Val14 and Gln39 establish a specific interaction with Mad in the context of PAH1. PAH1 
mutants indicated were fused to G4DBD and transformed with G4AD-TRX-Mad and subjected to quantitative 
E-galactosidase assay. Activity is displayed relative to G4DBD-PAH2/G4AD-TRX-Mad set at 100. A) Single 
amino acid replacement in PAH1 reveals M35L above background. B) M35L converts PAH1 into a weak 
transcription activator and allows detection of V7F. Control experiment with G4AD or without a prey was 
performed only for G4DBD-PAH1-M35L and G4DBD-PAH1-V7F-M35L. C) In the context of PAH1-V7F, 
L14V and K39Q enable a specific interaction with Mad-SID. D) In the context of PAH1-V7F-L14V, K39Q 
augments interaction with Mad-SID. E) PAH1-V7F-L14V-K39Q restores a specific interaction with Mad-SID 
at 30% of the level of PAH2. Indicated mutants were transformed in yeast strain Y190 with G4AD-TRX-Mad 
or as a control G4AD-TRX. E-galactosidase units activity and standard error are indicated. Results are the 







Given the ‘disturbing’ intrinsic transcriptional activity of PAH1-M35L we decided to re-
screen for second site mutations this time in the context of V7F. Combining PAH1-V7F with 
-L14V and to a lesser extend -K39Q, significantly boosted E-galactosidase levels while all 
other combinations remained at background levels (fig. 3C and E). Control experiments 
showed that the E-galactosidase level was strictly dependent upon the presence of Mad-SID. 
To test whether the affinity of the mutated PAH1 for the Mad-SID could be further 
improved, third site mutations were introduced this time in the context of PAH1-V7F-L14V 
(fig. 3D and E ). As expected from the second screen, K39Q increased the E-galactosidase
level (L11I and K36H showed modest effects). Interaction of PAH1-V7F-L14V-K39Q with 
Mad yielded E-galactosidase activity up to ~ 30% of that obtained with PAH2 and Mad in 
this yeast two hybrid setting. Remarkably, PAH1-L14V-K39Q yielded background levels of 
E-galactosidase reinforcing the critical role of F7 and suggesting that V14 and Q39 
contribute to the strength of the interaction, but do not represent the strongest determinants.  
Phe7 is critical in PAH2/Mad interaction 
To corroborate and extend the importance of PAH2 contact residues 7, 14 and 39 in the 
interaction with Mad-SID, these residues in PAH2 were mutated into the amino acid present 
at the respective positions in PAH1 and screened for their ability to interact with the Mad-
SID. Strikingly, PAH2-F7V completely abolished the interaction with Mad-SID, further 
substantiating its critical role (fig 4, A and B). Single mutations of V14L and Q39K 
displayed only a reduced but appreciable level of interaction between PAH2 and Mad (17.49 
and 8.71% respectively of PAH2/Mad wild type activity). Remarkably, the double mutant 
PAH2-V14L-Q39K still supported a low level but substantial interaction. When tested in the 
context of F7V, the V14L or K39Q alone or combined remained at background level. We 
conclude that F7 plays a key role in establishing the specific interaction between PAH2 and 
Mad-SID.
Figure 4. In the context of PAH2, Phe7 is critical for the interaction with Mad-SID. PAH2-F7V abolishes 
interaction with Mad-SID in vivo. PAH2 was mutated at critical position 7, 14 and 39 towards PAH1 
specificity, respectively F7V, V14L and K39Q. PAH2 indicated mutants were fused to G4DBD and 
transformed in yeast strain Y190 with G4AD-TRX-Mad or control G4AD-TRX. E-galactosidase units activity 
and standard error are indicated. Results are the average of at least five assays.   
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Structural determinants of the Mad-SID: constrains versus helical propensity 
In our assays, the Mad-SID was conformationally constrained by insertion into the surface 
loop of the TRX that is between two cysteines. In its native context, SID is located at the N-
terminus of Mad and can freely adopt any structure. Therefore, we evaluated the interaction 
properties of the PAH domains with the Mad-SID when displayed in a more flexible 
environment. To achieve this, a stop codon was inserted downstream of the Mad sequence 
before the second cysteine thus creating a C-terminus. In this C-terminal, ‘flexible’ context, 
Mad-SID strongly interacted with PAH2 but not detectably with PAH1 and hence the 
specificity of interaction was not altered in this context (fig 5A). The single mutants PAH1-
L14V and PAH1-K39Q remained at background levels (fig 5B) whereas a modest but 
reproducible interaction was obtained with PAH1-V7F. This modest gain of interaction is 
probably due to unleashing free helical properties. Similarly, the double mutants PAH1-V7F-
L14V and -V7F-K39Q displayed a 3-fold higher activity as compared to the constrained 
context. The PAH1-L14V-K39Q, i.e. lacking the critical V7F remained, at background level. 
The ‘flexible’ triple mutant displayed roughly equal E-galactosidase activity to ~30% as 
compared to the constrained version. These results show that free helicity plays an important 
role in establishing an interaction with Mad, but without a phenylalanine at position 7, 
unleashing of free helical properties is insufficient to support an interaction. 
The interaction of the ‘flexible’ Mad-SID with single PAH2 mutants V14L and K39Q or 
their combination yielded 5-fold higher level of E-galactosidase as compared to the 
constrained setting (fig. 5C). Mutation of F7V again abolished the interaction as observed in 
constrained conditions. Noticeably, the gain of free movement by Mad-SID tolerated and 
partially compensated for the loss of interaction due to V14L and Q39K but not when the 
mutation F7V is present.   
To extend and validate in a cell free system the observed role of PAH residues 7, 14 and 39 
in the interaction with Mad, we used the IgG pulldown assay. PAH1 and PAH2 mutants were 
fused to GST, purified and incubated with fixed amounts of immobilized protG-Mad bound 
to IgG Sepharose beads (fig. 5D). In the context of PAH1, Phe7 partially facilitated binding 
to Mad-SID, which was further enhanced with the inclusion of Val14 and/or Gln39. Val14 in 
the context of PAH1 displayed some binding to the Mad-SID whereas Gln39 was unable to 
support an interaction. Overall the in vitro data shows that Phe7 is the most contributing 
residue for binding followed by Val14 and Gln39. In the reverse situation, mutation in PAH2 
of Phe7 abolished the interaction in vitro as observed in the yeast two hybrid setting. 
Mutating Gln39 in PAH2 slightly affected the interaction whereas no effect could be 
observed when Val14 was mutated. Combining Phe7 and Gln39 mutations yielded 
background level as observed in vivo. Mutations combining Phe7 and Val14 in PAH2 
resulted in a substantial interaction whereas no effect could be observed from combining 
Val14 and Gln39. We conclude that the phenylalanine at position 7 is the specific, critical 
molecular determinant of complex formation between PAH2 and Mad-SID in vivo in a yeast 






























































Figure 5. Free Helicity of Mad is a molecular determinant for residue 7, 14 and 39 of the PAH1 and PAH2 
domains of mSin3b. Indicated PAH mutant fused to G4DBD were transformed in yeast with G4AD-TRX-Mad 
or a C-terminal truncated variant G4AD-TRX-Madstop and subjected to quantitative E-galactosidase assay. E-
galactosidase units activity and standard error are indicated. Results are the average of at least five assays. A)
Free helicity stabilizes interaction of PAH2 with Mad. B) Free helicity provides 3 fold increase in level of 
PAH1-V7F-L14V and PAH1-V7F-K39Q and detection of PAH1-V7F. C) Free helicity compensates for V14L
and Q39K effect at the PAH2 domain of mSin3b. D) Igg pulldown confirms critical role of Phe7 in vitro. Equal 
amounts of GST-PAH1 or GST-PAH2 mutated proteins were incubated with fixed amounts of ProtG-Mad-
SID(5-24) bound to IgG-sepharose and washed extensively. Bound material was eluted, separated on SDS-
PAGE and coomassie blue stained.  
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Discussion 
In this study we employed NMR structural information and homology modeling to direct a 
mutagenesis screen and identify amino acids conveying specificity of PAH2/Mad-SID 
interaction. Introduction of PAH2 contact residues Phe7, Val14 and Gln39 at their 
corresponding position in PAH1 enabled a specific interaction with the Mad-SID in vivo and 
in vitro. Phe7 at the PAH1 domain restores on its own an interaction with the Mad-SID in a 
free helical environment whereas Val14 and Gln39 stabilize this interaction. Furthermore we 
showed that mutation of Val14 and Gln39 in PAH2 were not critical for the interaction with 
Mad-SID, as opposed to the change of Phe7 into a Val which abolished the interaction. 
Overall, these results demonstrate that Phe7 conveys to a large extend the specificity of the 
interaction between PAH2 and Mad-SID in vivo in a yeast two hybrid setting and in vitro in a 
pulldown assay. 
An analysis of interatomic Contacts of Structural Units (CSU) on the NMR structure of the 
PAH2 domain of msin3b with the Mad-SID reveals possible molecular contacts of Phe7, 
Val14 and Gln39. Gln39 sidechain displays some atomic contacts with Leu13 of the Mad-
SID. Mutating Gln39 to a Lys does not change the length of the sidechain, but changes the 
charge. Thereby Lys39 would maintain atomic contacts with Leu13 of the Mad-SID and thus 
not provide an explanation for Gln39 stabilizing role. Remarkably, Gln39 displays many 
hydrophilic-hydrophilic contacts with other PAH2 residues such as His36, Thr37, Tyr38, and 
Gln42. Thus, Gln39 could have therefore an important role in charge maintenance. A lysine 
mutation would lead to a unilateral positive charge and as a consequence these hydrophilic-
hydrophilic interactions could be affected and disturb the folding of PAH2.  
Careful inspection of the NMR structure with respect to Val14 residue as well as CSU 
analysis shows intermolecular contacts with conserved residues Leu12, Ala15, Ala16 and 
Leu19 of the Mad-SID. It was already remarked, that the short side chain of Ala15 and Ala16 
of the Mad-SID might play a crucial role in allowing the maintenance of the PAH2/Mad-SID 
interface. Val14 fits in a hole formed by Ala15, Ala16 and Leu19 of the Mad-SID (38). 
Replacement of Val14 with a leucine would increase the sidechain length. This increase 
could generate a distance as close as 2.4 Å between Leu14 in PAH2 and Ala15 in the Mad-
SID. It suggests that Leu14 bumps into the Mad-SID and thus explains our results with the 
PAH2 -V14L mutation. The PAH1 molecular model depicts a distance as close as 2.2 Å 
between Leu14 and Ala15 and 2.6 Å between Leu14 and Ala15. Proper contact distances can 
be restored when introducing the PAH1-L14V mutation. Distance can be measured as close 
as 3.4 Å between val14 and Ala15ȱ and 4.4 Å between Val14 and Ala15 (fig. 6), overall 
strengthening the stabilizing role of Val14. 
Strikingly CSU analysis of PAH2 residue Phe7 depicts a contact with Mad-SID residue 
Tyr18. Careful inspection of the surrounding of PAH1 Phe7 in our molecular model suggests 
contact with the Mad-SID aromatic residue Tyr18. A distance as close as 3.7 Å can be 
measured between those residues (fig. 6). Based on results from our experiments, structural 
information and modeling, most likely a stacking interaction between the aromatic rings of 
Phe7 and Tyr18 is the key to the complex formation between PAH2 and Mad.  
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Figure 6. Model of interaction between PAH1-V7F-L14V and Mad SID. PAH1 molecular model was generated 
with WHAT IF and further mutated towards PAH2 specificity in order to generate PAH1-V7F-L14V. 
Molecular Graphics were generated using YASARA and POVRAY. PAH1-V7F-L14V is displayed in blue and 
Mad-SID(5-24) is displayed in orange. Distances (Å) between presumed contact residues are indicated.  
In conclusion, interaction between the Sin3 co-repressor, the tumor suppressor Mad and other 
PAH interactors appear to be characterised by conserved properties such as amphipaticity 
and D helicity and reach their specificity at a molecular level through residues such as Phe7 
that is present only at the PAH2 domain of Sin3. Open questions remain on understanding 
the specificity of PAH1, PAH3 and PAH4 and their interacting partners. Consensus 
sequences for PAH interacting protein are still unsolved and subject to many questions. 
Ultimately a definition of the specificity of every PAH domain can provide a new way to 
identify the residues required and needed in amphipatic D helix motifs of Sin3 interacting 
member, enlarging our molecular view on the role of the Sin3 co-repressor complex in 
transcriptional repression and cell growth.   
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Abstract
Sin3 is the central component of a multisubunit complex involved in transcriptional 
repression. A number of DNA binding proteins are targeted by the Sin3 complex to 
chromatin through association with its PAH (paired amphipathic helix) domains. The 
binding specificity and selectivity of the Sin3 PAH domains, however, has remained 
poorly understood. Here, we performed a yeast two hybrid screening using a peptide 
aptamer library and identified peptides that specifically interact with either PAH1 or 
PAH2. Analysis of PAH2 interacting peptides uncovered motifs similar to previously 
characterized PAH2 interacting proteins Mad, Ume6 and kruppel like family 
members while analysis of PAH1 interacting peptides revealed an LVXLL motif. In 
addition, a Tap-tagging approach of Sin3b resulted in the isolation of a number of 
known and novel interactors amongst which neural retina leucine zipper, NRL. 
Strikingly, one of the identified PAH2 interacting peptide aptamers showed strong 
resemblance to a sequence motif present in NRL and direct association between 
PAH2 and NRL was shown. Finally, we reveal that PAH1 and PAH2 amino acids 7, 
14 and 39 previously shown to be important for Mad-PAH2 interaction, also play an 
important role in the specificity of interaction between PAH1, PAH2 and identified 
aptamers. Our results provide novel insights into the molecular determinant of the 




Transcriptional regulation is central in many cellular functions including 
differentiation and development. In eukaryotes, alteration of chromatin structure plays 
an integral role in gene regulation. Such chromatin changes occur on core histone tails 
at a post translational level and are induced by different classes of enzymes including 
histone acetyl transferases (HAT) or histone deacetylases (HDAC) (1,2). Recruitment 
of HAT complexes to genes generally results in transcription activation while 
recruitment of HDACs results in transcriptional repression (3,4).  The Sin3 protein is 
an evolutionary conserved repressor that is part of a ~1.2 MDa multi-protein co-
repressor complex associated with HDAC activity. The core subunits of the Sin3 
complex includes HDAC1, HDAC2, RbAp46/48, RBP1, SAP130, BRMS1, SDS3, 
SAP30 and SAP18 (5-11).
Sin3 contains four conserved imperfect repeats of ~100 amino acids termed paired 
amphipathic helix (PAH) domains which are protein-protein interaction modules for 
an array of DNA binding transcriptional repressors (12). PAH1 has been reported so 
far to interact with Opi1, Pf1, NRSF, N-CoR and SMRT (13-17). The PAH2 domain 
covers a broad range of interactions including Mad protein family members, Sp1-like 
repressor poteins, HBP1, Pf1 and yeast Ume6 (14,18-23).  
The interaction of Sin3 with the tumor suppressor Mad is particularly well studied. 
The ability of Mad to inhibit cell proliferation and to repress transcription is 
dependent on a N-terminal N8IQMLLEAADYLE20 domain named SID (Sin3 
interacting domain) (22,24). In nuclear magnetic resonance experiments, Mad SID 
folds as an amphipatic helix and contacts the PAH2 domain of Sin3 which folds as a 
four helix bundle (25-27). A recent study from Swanson and co-workers revealed a 
reverse N-terminal to C-terminal orientation of the HBP1 SID amphipatic helix in 
contact with PAH2 as compared to the Mad SID. Furthermore, molecular dynamic 
simulation has suggested that TIEG2 SID binds PAH2 in a different orientation than 
the Mad SID, suggesting multiple ways to interact with PAH2 (23,28). 
Initial attempts to identify a SID consensus sequences for Mad family members 
revealed the following degenerated sequence: ĳZZĳĳXAAXXĳnXXn with X for any 
non-proline residues, ĳ for bulky hydrophobic residues and n for negatively charged 
residues (25-27). Other studies have reported the SID of SP1-like members with 
PAH2 as ĳĳXAAXXĳ. Despite a wealth of information on PAH2 and interacting 
SIDs, PAH1 remains poorly characterized and the identification of a PAH1 
interaction motif has not been reported. 
Here, we screened peptide aptamer libraries to identify PAH1 and PAH2 interacting 
peptides. Different motifs interacting with PAH1 and PAH2 are presented. We show 
that binding of the identified aptamers to the PAH1 or PAH2 domains is affected by 
PAH1 and PAH2 mutations previously shown to be important for an interaction with 
the Mad SID (29). A complementary approach using tap-tagging of mSin3b revealed 
in addition to proteins that are part of the core Sin3/HDAC complex, a novel 
transcription factor NRL, a leucine zipper protein which contains an amino acid 
sequence similar to one PAH2 aptamer.  
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Materials and methods: 
Cloning and binding assay: 
Oligos containing a BamHI restriction site overhang followed by P1-1 
EGDWLFFVLLVGLL or P1-8 SAAMGSAEFEALVALLFLSEE encoding 
sequences and an EcoRI restriction site overhang were annealed, phosphorylated and 
ligated in frame to the GB1 domain of streprococcal protein G using BamHI and 
EcoRI site of pGEV2 plasmid. A fragment encompassing mSin3b was subcloned 
from pvzmSin3b (20) into EcoRI and BamHI site from pZXN. pZXN has been 
described in another study and contains one ProtA domain, two TEV cleavage sites 
and a myc epitope. NRL was amplified by PCR from plasmid pcDNA4-NRL using a 
forward primer containing an EcoRI restriction site overhang with a myc tag 
(MEQKLISEEDL) in combination with a reverse primer containing a BamH1 
restriction site and after digestion by EcoRI/BamHI was ligated into pSG5(stratagene) 
(30). All constructs and positive aptamers vectors were validated by DNA 
sequencing.
The P1-1 and P1-8 or mutant aptamers fused to the GB1 domain of streprococcal 
protein G was prepared as described earlier (25). GST-PAH1 (amino acids 34-108) 
and GST-PAH2 (amino acids 148-252) and their respective mutants at position 7, 14 
and 39 were expressed and purified as described previously (31).
GST-PAH1 or PAH2 (10Pg) and their respective mutants were incubated with protG-
P1-1 or protG-P1-8 and bound to IgG-Sepharose (Pharmacia) in 150 mM NaCl, 0.1% 
NP-40, 20 mM Tris  pH 7.6. Beads were washed 3 times with the same buffer. Bound 
proteins were eluted with 0.1 M Glycine pH 2.6, separated by SDS gel 
electrophoresis, and coomassie blue stained. 
40 Pg of mycNRL were transfected in 293 HEK cells on a 14 cm dish using calcium 
phosphate method. Whole cell extract was prepared 36 hours after transfection as 
described previously (32). Subsequently, extracts were incubated in 3 volumes of 
IPP150 (10mM tris, 150mM NaCl, 0.1% NP-40 and 0,5mM EDTA) and equal 
amount (2Pg) of GST-PAH1 or GST-PAH2 and GST-Sepharose 4B (Amersham). 
After 1 hour incubation at 4 ºC on a rotating wheel, beads were washed three times 
with 20 beads volumes of IPP150. Bound fraction was subjected to SDS-PAGE and 
western blotting using D-myc monoclonal antibody (9E10).     
Yeast two hybrid screening: 
Yeast strain KF1 (MATa trp1-901,leu2-3,112 his3-200 gal4D gal80D LYS2::GAL1-
HIS3 GAL2-ADE2 met2::GAL7-lacZ SPAL10-URA3) was used for the screening. As a 
bait the PAH1 or the PAH2 domain of mSin3b were fused in frame with the GAL4 
DNA binding domain in vector pcp97 described previously (29). The yeast prey 
vector padTRX  encodes the Escherichia coli thioredoxin A (trxA) gene fused to the 
Gal4 activation domain. The 20 amino acid randomized peptide library was inserted 
in the RsrII site of trxA which corresponds to a constrain loop and was estimated to be 
of a complexity of 2x108 individual members (33). KF1 containing a PAH1 or  PAH2 
bait was transformed using LiAc method with the peptide aptamer expression library 
and was first selected for growth on media lacking adenine. Subsequently KF1 
positive transformants were replica plated on media lacking histidine in the presence 
of increasing concentration of the inhibitor 3-amino-triazole(3AT) as indicated. 
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After rescue of the positive aptamer expression vectors, the PAH binding specificity 
was established in the Saccharomyces cerevisiae Y190(clontech) strain using PAH1 
and PAH2 mutants described previously (29). Quantitative E-galactosidase assay were 
performed using O-nitrophenyl E-D-galatopyranoside (ONPG) as a substrate. Fresh 
transformants were grown overnight in 5 ml SD-leu-trp selective culture medium; 1.5 
ml cells were concentrated 5 times in buffer Z (60 mM Na2HPO4, 60 mM NaH2PO4, 
10 mM KCl, 1 mM MgSO4 pH 7.0). Cells were resuspended in 100 Pl buffer Z and 
freeze thawed. 0.7 ml buffer Z supplemented with 50mM E-mercaptoethanol and 160 
Pl (4mg/ml) ONPG was added to initiate the reaction. Incubations for 30min up to 2 
hours were performed at 30qC. Reactions were stopped with 0.4ml of 1M Na2CO3. E-
galactosidase units were calculated according to the formula  E-galactosidase
units(Pmol ONPG.min-1)=1000*OD420/(time in min*0.1*5*OD600). Experiments were 
repeated at least 3 times and in triplicate. 
Results
Identification of PAH1 and PAH2 aptamers 
The PAH2 domain of Sin3 associates with a number of proteins and the interaction 
domains determine a tentative consensus SID. A PAH1 interaction consensus has, 
however, not been determined. Therefore, we performed a peptide library screen to 
identify specific PAH1 and PAH2 interacting peptides. We screened a random 
constrained 20-mer peptide library displayed on the active site loop of E. coli
thioredoxin (TRX) molecule fused to the Gal4 transcription activation domain in a 
yeast two hybrid assay. The PAH1 or the PAH2 domain of mSin3b were fused to the 
DNA binding domain of Gal4 (G4DBD) and used as baits. Interaction between baits 
and preys yields transactivation of the reporter gene GAL1-HIS3 and consequent 
growth on media lacking histidine. The relative strength of the interaction was 
assessed by determining resistance to the histidine biosynthesis inhibitor 3-amino-
triazole (3AT). As a control prey, we used the previously described Mad-SID (G4AD-
TRX-Mad) known to specifically interact with PAH2 (29). Mad-SID combined with 
PAH2 supported growth of yeast on media lacking histidine supplemented with 
50mM 3AT whereas Mad-SID combined with PAH1 did not support growth. Thus, 
Mad specifically interacts with PAH2 in this assay (fig. 1A). Screening 106 and 2*106
transformed yeast clones for PAH1 and PAH2 interactors led to the isolation of eight
and eleven different transformants, respectively (fig. 1A and 1B). Transformants 
showed growth in the presence of 50mM up to 100mM 3AT for PAH1 aptamers and 
from 10mM up to 100mM 3AT for PAH2 aptamers. After isolation of the prey 
plasmid, the sequence of the peptide insert was determined (table 1).  
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Figure 1. Identification of aptamers interacting with the PAH1 or the PAH2 domain of mSin3b in a 
yeast two hybrid screen. Yeast containing a control Mad1 SID sequence (5-24) fused to Gal4AD in 
combination with PAH2 fused to Gal4DBD is able to survive on media lacking histidine with 50mM 
3AT while yeast containing Mad1 and PAH1 fused to G4DBD was not able to support growth. Yeast 
containing PAH1 aptamers (p1-1 to p1-8) with a G4DBD-PAH1 or PAH2 aptamers (p2-1 to p2-11) 
with a G4DBD-PAH2 survived on media lacking histidine supplemented with at least 50mM 3AT. 
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Table 1: Sequence of peptide aptamers identified from a screening with a G4DBD-PAH1 or G4DBD-
PAH2 bait. * indicates a truncated peptide. 
Aptamers binding to the PAH1 domain of mSin3b 
P1-1  EGDWLFFVLLVGLL* 
P1-2        LACRCWRCVHTRVRLLW * 
P1-3      VDVYGSFGLLWCFECFVSEC 
P1-4        LWLLSEVSSVYGT* 
P1-5         SLALYASIWLLAEHWPQGLI
P1-6        WSLTWVPLYVLTMCAYWRSL  
P1-7         DRLSCFWCWWLVFLTHHAAG 
P1-8 AAMGSAEFEALVALLFLCEE  
Aptamers binding to the PAH2 domain of mSin3b 
P2-1         NLGLLVLGSVCTFRLGLL* 
P2-2         VDSAWAALLSVACCSLWGLV
P2-3        EGCVVVDWAAWVLVGYAAGW 
P2-4 MPSSLNFGSFMGASLWGPLVIAFFLRFRRTGLFLLWVV*
P2-5         WWAWLSVKLGHSGDWLVSLF  
P2-6         VVFLCFLDSLSCAVDAAGDD 
P2-7         GVFFVFLLWTSMPSAESTSM 
P2-8         SSPYCSSRWKILSF* 
P2-9      FYLWMLSRGGSGPMLLQIVL 
P2-10       CMWLMGHSMRLILIWCACMT 
P2-11 VEHCDFCCTVAALVLMSRES
The FXXLVXLL motif is a PAH1 interacting motif 
To characterize the identified PAH1 aptamers we first analysed their specificity. We 
retransformed each prey with PAH2 or PAH1 in YN1 yeast strain and performed 
quantitative Beta Galactosidase assay. Background levels were observed for every 
PAH1 aptamer in combination with G4DBD-PAH2, showing that interaction between 
PAH1 recovered aptamers and PAH1 was specific (fig. 2A).  
We reported previously that introduction of PAH2 residues Phe7, Val14 and Gln39 at 
their corresponding position in PAH1 enables a specific interaction with Mad, a 
PAH2 specific interacting protein and showed that PAH2 residues Phe7, Val14 and 
Gln39 play an important role in determining the specificity of the PAH2-Mad 
interaction. Assuming that amino acids at the respective position in PAH1 play a 
similar role in determining the specificity between PAH1 and PAH1 aptamers, we 
hypothesized PAH1 residues Val7, Leu14 and Lys39 to be specific molecular 
determinant of PAH1-PAH1 aptamers interaction.  
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Figure 2. Analysis of the interaction of PAH1 aptamers in vitro. (A)  PAH1 aptamers fused to G4AD 
were assayed in liquid culture to examine E-galactosidase activity either in the presence G4DBD fused 
to PAH1, PAH2. (B) E-galactosidase assay of PAH1 aptamers in the presence of G4DBD fused to 
PAH1 single or double mutant V7F and L14V. (B) Sequence alignement of P1-1 and P1-8 showing 
conservation of an FXXLVXLL motif. (C) Helical wheel of P1-1 and P1-8. Arrows depict 
FXXLVXLL residues localized within one side of the helix in P1-1 or P1-8. 
To test this assumption, we assessed whether binding of the aptamers to PAH1 was 
affected by mutating the amino acid Val7 and Leu14 into Phe7 and Val14 
respectively as they appear in PAH2. All PAH1 aptamers except P1-4 showed 
A
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complete loss of interaction upon mutation of L14V; aptamers that interacted weakly 
with PAH1 were also strongly affected by the V7F mutation (fig. 2B).  Despite an 
impaired interaction of PAH1 L14V with PAH1 aptamers, PAH1 V7F L14V double 
mutant readily associated with PAH1 aptamers suggesting that in a double mutant 
context, V7F mutation partially suppressed the critical effect of L14V mutation. We 
conclude that PAH1 Leu14 is a critical residue for binding of PAH1 aptamers in our 
yeast two hybrid assay.
P1-1 and P1-8 boosted relatively high level of the reporter gene activity and 
inspection of amino acid sequence revealed the shared motif FXXLVXLL (fig. 2C). 
Secondary structure prediction showed a preference for P1-1 and P1-8 to adopt an D-
helix and a helical wheel projection showed that the FXXLVXLL motif is placed on 
one surface of the D-helix. Such a structural characteristic has also been described in 
the SID of Mad family members that bind PAH2 (fig. 2D).  
Figure 3. Analysis of the interaction between PAH1 and the FXXLVXLL motif in vitro. (A) Igg 
Pulldown of P1-1 and P1-8. P1-1 and P1-8 were fused to ProtG and incubated with GST fused to 
PAH1, PAH2, PAH1 single, double or triple mutant V7F, L14V and K39Q and washed extensively. 
Bound material was eluted, separated on SDS-PAGE, and Coomassie Blue-stained (B) Alanine scan 
strategy. Every established mutants used are shown. (C) Igg Pulldown of FXXLVXLL mutants of P1-
8. Every mutant of P1-8 were fused to ProtG and incubated with GST-PAH1. Bound material was 
eluted, separated on SDS-PAGE, and Coomassie Blue-stained. Top panel depicts input of the different 
P1-8 mutants used while bottom panel depicts the GST-PAH1 bound fraction after Igg pulldown. 
To corroborate and validate the interaction between PAH1 and P1-1 or P1-8, in vitro
pulldown assay were performed. We expressed and purified a fusion protein 
consisting of the ProtG domain followed by P1-1 or P1-8 that were incubated with Igg 
beads in the presence of GST-PAH1, GST-PAH2 or GST-PAH1 mutants. A direct 
interaction with PAH1 but not PAH2 was observed, thus confirming the PAH1 
domain specificity of the aptamers (fig. 3A). The L14V point mutation in PAH1 
impaired binding to P1-1 and P1-8 while a modest decrease in binding was observed 
with V7F, confirming and extending the yeast two hybrid observations. Furthermore 
substitution of Lys39 in PAH1 with Gln39, the amino acid present in PAH2 on that 
position, abolished the interaction with P1-1 and P1-8. As previously observed in 
yeast two hybrid experiments, PAH1 V7F L14V double mutants interacted with P1-1 
and P1-8 in contrast to PAH1 L14V single mutant which did not associate with P1-1 
and P1-8. This subtle difference suggests that in a PAH1 V7F L14V context, PAH1 
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V7F mutation suppressed the critical effect of PAH1 L14V mutation. Double mutant 
V7F K39Q and triple mutant V7F L14V K39Q did not associate with either P1-1 or 
P1-8. We conclude that Leu14 and Lys39 in PAH1 are critical amino acids for 
interaction while Val7 may only have a stabilizing role.  
To establish the importance of the proposed FXXLVXLL motif for an interaction 
with PAH1, an alanine scan of P1-8 was performed on the presumed conserved 
residues of the postulated motif and tested in Igg pulldown assay with GST-PAH1 
(fig. 3B and C). Mutating Leu15 or Leu16 severely destabilized the interaction 
between the motif and PAH1 while mutating Leu12 significantly enhanced binding. 
Mutating Phe9 or Val13 displayed only minor effects. Therefore Leu15 and Leu16 in 
P1-8 are critical for interacting with PAH1 whereas Leu12 can be mutated into an 
alanine to increase in vitro binding of p1-8 to PAH1.
Specificity of PAH2 aptamers 
The binding specificity of PAH2 peptide aptamers was assessed as described for 
PAH1 (fig. 4A). Each of the PAH2 aptamers displayed low level of interaction when 
retransformed with PAH1, indicating that interaction between PAH2 recovered 
aptamers and PAH2 was specific.  
We have previously shown that introduction of PAH1 residues Val7, Leu14 at their 
corresponding position in PAH2 impairs interaction with Mad indicating that PAH2 
residues Phe7, Val14 play an important role in specificity between PAH2 and Mad 
interaction (29). Therefore we assumed that PAH2 residues Phe7 and Val14 may also 
play an important role in the specificity of interaction between PAH2 specific 
aptamers and PAH2. The interaction between PAH2 and the aptamers was assessed 
upon mutating conserved PAH2 residues Phe7 and Val14 to the corresponding PAH1 
residues Val7 and Leu14. F7V or L14V substitutions in PAH2 affected binding of 
most aptamers apart from P2-7 and P2-11(fig. 4B). The double PAH2 mutant F7V 
V14L failed to interact with any of the aptamers except P2-7. These results thus 
corroborate and extend the importance of these PAH2 residues for the interaction with 
Mad to other PAH2 interacting aptamers (29).  
Two striking observations were made upon visual inspection of the PAH2 aptamers 
sequences. First, the strongest PAH2 aptamer P2-2 shows homology to sequences of 
the PAH2 SIDs from Pf1 and Mad family members. Second, P2-3, P2-11 and P2-6 
share an A[AV]X[VA][LV]  motif and show homology to SIDs from TIEG1 and 2, 
Ume6, HBP1, and BTEB4 (fig. 4C). This suggests that the PAH2 domain of Sin3 can 
recruit two types of SIDs, Mad-like high affinity SIDs and moderate affinity SIDs 
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Figure 4. Analysis of the interaction of PAH2 aptamers. (A)  PAH2 aptamers fused to G4AD were 
assayed in liquid culture to examine E-galactosidase activity either in the presence G4DBD fused to 
PAH1, PAH2. (B) E-galactosidase assay of PAH2 aptamers in the presence of G4DBD fused to PAH2 
single or double mutant F7V and V14L. (C) Sequence alignement of P2-2 and 2-5 showing homology 
to the SID of Mad, Mad from Caenorhabditis elegans and Pf1 (top panel) Sequence alignment of P2-3, 
P2-6 inverted sequence and P2-11 matching an A[AV]X[VA][LV] motif conserved in Ume6, HBP1, 
BTEB4, TIEG1 and TIEG2 SIDs (middle panel). SID from potential PAH2 interacting proteins 
matching the A[AV]X[VA][LV] motif include residue 65 to 58 from BTB and kelch domain 
containing protein 5 (accession number Q96NJ5)  an residue 1070 to 1063 from BTB/POZ domain 
containing protein 12 (accession number Q8IY92) (bottom panel). 
Purification of TAP tagged mSin3b and association with NRL: 
Although a few peptide aptamers displayed homology to the putative PAH2 
interactors BTB5 and a BTB/POZ domain containing protein 12 (fig 4C), we 
embarked on a different but complementary experimental strategy to identify Sin3 
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interacting proteins by purifying a Tap-tagged Sin3b complex from human embryonic 
kidney (HEK 293) cells. Analysis of the purified Sin3b complex by silver stain 
showed several bands which were absent from a control purification using extract 
from wild type cells. To identify the composition of the Sin3b complex preparation, 
nano LC-FT-ICR MS analysis was performed (fig. 5A). As judged from % sequence 
coverage and number of peptides per protein, HDAC1, HDAC2 and Sin3b were 
present at stoichiometric levels whereas the histone binding proteins RbAp46/48, 
HDAC1 binding protein SDS3, RBP1, SAP130, breast cancer metastasis suppressor 
BRMS1 and Sin3a were present in sub-stoichiometric amounts (fig. 5B). These 
results suggest that we purified a Sin3b sub-complex composed exclusively of Sin3b 
and HDAC1/2 as well as a complete complex composed of Sin3a, HDAC1/2 and the 
other known subunits. FT-MS analysis also revealed mono-methylation on K386 of 
mSin3b, a conserved lysine residue localized in the SDS3/HDAC interaction domain 
(fig 5C). 
In addition to proteins that are part of the Sin3/HDAC complex, peptides matching to 
the transcription factors Pf1 and Mad1 were identified that are known to interact with 
the Sin3/HDAC complex. Thus this new tagging/proteomic procedure can be used to 
identify interacting transcription factors. NRL (Neural Retina Leucine zipper) known 
transcription factor was also detected in the FT-MS analysis, suggesting that it 
interacts with the Sin3/HDAC complex. Visual inspection of the NRL amino acid 
sequence revealed a short predicted D helical stretch with a striking homology to 
aptamer P2-11 suggesting that NRL and the PAH2 domain of Sin3b may indeed 
interact (fig. 5D). To directly test an interaction between PAH2 and NRL, GST 
pulldown experiments were performed. Extracts derived from cells transfected with 
myc-tagged NRL were incubated with equal amounts of GST-PAH2 or GST-PAH1 
and GST-beads. A specific interaction between NRL and GST-PAH2, but not with 
GST-PAH1, could be detected, providing biochemical evidence for a direct 
interaction between NRL and the PAH2 domain of mSin3b. (fig. 5E) 
In conclusion the experiments described in this study establish one interaction motif 
for PAH1 and two different motifs for the PAH2 domain of the Sin3 transcriptional 

























Peptide Mascot score         delta means



























Figure 5. Tap tagging purification of mSin3b and FT/MS analyses reveals NRL as a new PAH2 
interacting protein. Stable cell line, TAP tagging procedure and FT/MS analysis have been described in 
another study (32). (A) Silver stained gel of purified mSin3b complex from HEK 293 cells. mSin3b is 
indicated with an arrow. (B) FT-MS/MS analysis with all identified proteins and their respective 
peptide numbers and Mascot score. (C) FT-MS/MS profile of mSin3b peptide with methylation on 
K386. (D) Sequence alignement of putative PAH2 SIDs of NRL (residue 125 to 150) with P2-11. (E) 
Western blot of a GST pulldown experiment using myc-NRL, GST-PAH1 and GST-PAH2. After 
extensive washing, bound material was eluted, separated on SDS-PAGE, and subjected to western 
blotting using D-myc antibody. Bottom panel depicts input form GST-PAH1 and GST-PAH2 used in 
this experiment on a SDS-PAGE coomassie blue stained. 
Discussion:
In this study we have used two different approaches to identify PAH1 and PAH2 
interacting proteins.  By performing a yeast two hybrid screening of a peptide aptamer 
library we have identified a small repertoire of peptides interacting specifically either 
the PAH1 or PAH2 domain of mSin3b. Two high affinity PAH1 binding aptamers 
contained an LVXLL motif. Three PAH2 binding aptamers shared an 
A[AV]X[VA][LV] motif included in Ume6 or Kruppel like family members. One 
high affinity PAH2 binding aptamer contained an LLXXA motif previously shown to 
be part of the SID of Mad family members. A search with the A[AV]X[VA][LV] 
motif yielded the BTB and kelch containing protein 5 (BKLHD5) and the BTB-POZ 
domain containing protein 12. Our results therefore suggest that BTB containing 
proteins could potentially have a repressive function on transcription through 
recruitment of the Sin3/HDAC complex. Additional studies are required to test this 
prediction.
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We had previously shown that introduction of PAH2 contact residues Phe7, Val14 
and Gln39 at their corresponding position in PAH1 enabled a specific interaction with 
Mad, a PAH2 interacting protein (29). We therefore hypothesized that PAH1 residues 
Val7, Leu14 and Lys39 play an important role in the specificity between PAH1 and 
PAH1 aptamers. Conversely we hypothesized that PAH2 residue Phe7, Val14 and 
Gln39 play an important role in the specificity between PAH2 and PAH2 aptamers. 
The majority of the identified PAH1 aptamers were indeed affected in their 
interaction with PAH1 when Val14 was introduced. Furthermore the LVXLL-type 
aptamers were unable to bind to PAH1 upon introduction of Val14 or Gln39. In 
contrast the majority of PAH2 aptamers were strongly disturbed in their binding when 
Val7 and Leu14 of PAH1 were introduced into PAH2 as previously shown for the 
Mad-SID. We therefore speculate that residue 7, 14 and 39 indeed play a determining 
role in the specificity of interactions between PAH1 and PAH2 and their respective 
interacting partners.
In a complementary approach to identify novel Sin3 interacting proteins, we purified 
TAP-tagged mSin3b complex stably expressed in HEK 293 cells and identified 
known Sin3 complex subunits. We observed co-purification of Sin3a, SDS3, RBP1 
and SAP130. The approach also yielded the co-purification of several transcription 
factors, such as Mad and Pf1 as well as a novel protein, Neuronal Retina Leucine 
zipper protein (NRL). Mad and Pf1 are known Sin3 PAH2 interactors whereas NRL a 
bZip transcription factor involved in the regulation of rhodopsin gene activity had 
previously not been linked to Sin3-dependent repression. Interestingly, reporter assays 
have shown that amino acids 30 to 93 of NRL encompass a minimal transactivation 
domain and that this domain has a substantially higher activation potential than full 
length NRL or a fragment encompassing amino acid 30 to 143. These previously 
described results suggested that amino acids 93 to 143 can affect the degree of NRL 
transactivation. Our observation that NRL interacts directly with PAH2 and the high 
similarity of NRL region 125-150 with a PAH2 aptamer can be reconciled with the 
work from Friedman et al to hypothesize a recruitment of Sin3/HDAC co-repressor 
complex in the NRL region 125-150 that suppresses the N-terminal transcriptional 
activity of NRL (30). Additional studies will be required to address the role of the 
Sin3/HDAC complex in NRL function.  
In conclusion we identified two interaction motifs for the PAH2 domain, a Mad-like 
motif and an A[AV]X[VA][LV] motif. We also identified one LVXLL containing 
motif for the interaction with the PAH1 domain. We reveal that one PAH2 aptamer 
shows homology to a novel protein neural retina leucine zipper which was identified 
using TAP-tagging purification of mSin3b. Finally we show that the specificity of the 
identified aptamers for an interaction with either the PAH1 or PAH2 domain depends 
upon the amino acids at position 7, 14 and 39 of PAH1 and PAH2, respectively. Thus, 
this study provides new insights into the molecular determinants of the specificity of 
PAH1 and PAH2 for their interacting partners. Unraveling the structure of the PAH1 
domain in complex with their natural binding partner and elucidation of the 
specificities of alpha helical motifs ultimately will help to further uncover the 
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The human genome contains a number of methyl CpG-binding (MBD) proteins that 
translate DNA methylation into a physiological response. To gain insight into the 
function of MBD2 and MBD3, we first applied protein tagging and mass 
spectrometry. We show that MBD2 and MBD3 assemble into mutually exclusive 
distinct Mi-2/NuRD-like complexes, called MBD2/NuRD and MBD3/NuRD. We 
identified DOC-1, a putative tumor suppressor, as a novel core subunit of 
MBD2/NuRD as well as MBD3/NuRD. PRMT5 and its co-factor MEP50 were 
identified as specific MBD2/NuRD interactors. PRMT5 stably and specifically 
associates with and methylates the RG rich N-terminus of MBD2. Chromatin 
immunoprecipitation (ChIP) experiments revealed that PRMT5 and MBD2 are 
recruited to CpG-islands in a methylation dependent manner in vivo and that H4R3, a 
substrate of PRMT, is methylated at these loci. Our data shows that MBD2/NuRD and 
MBD3/NuRD are distinct protein complexes with different biochemical and 
functional properties.




Methylation of CpG dinucleotides in regulatory regions of genes is an important mark 
for epigenetic regulation of transcription (1). Since DNA methylation is passed on to 
daughter cells during cell division, these methyl CpG marks can be maintained during 
development and provide epigenetic memory (2). A number of proteins has been 
identified in the human genome that can specifically bind to methylated CpG residues 
via a methyl CpG binding domain (MBD) (3,4). Recruitment of these proteins to 
promoters containing methylated CpG rich stretches -CpG islands- is thought to result 
in modulation of chromatin structure and repression of transcription. The human 
genome encodes five MBD proteins: MeCP2 and MBD1-4 (5-7). Apart from MBD3, 
these proteins have been shown to have specific methyl CpG binding activity. 
Recently a novel protein, Kaiso, was identified as a methyl CpG binding protein even 
though this protein lacks a classical MBD but appears to bind specifically to 
methylated DNA via a zinc finger domain (8).  
Several MBD proteins have been reported to interact with histone deacetylases as well 
as histone methyltransferases. MeCP2 has been described to interact with the 
Sin3/HDAC co-repressor complex (9), Brahma (10) as well as with the histone H3 
lysine 9 methyltransferase Suvar 3-9 (11), although these interactions may not be 
stable since MeCP2 is mostly present inside the cell as a monomer (9,11-13). MBD2 
and MBD3 have been identified as core subunits of the Mi-2/NuRD complex (14,15), 
whereas Kaiso is part of the HDAC-containing N-CoR complex that plays an 
important role in transcription regulation by nuclear hormone receptors (15-17). 
Collectively, these findings suggest a functional link between DNA methylation, 
histone deacetylation and histone methylation and indicate that these epigenetic 
events functionally cooperate to regulate transcription and cellular memory.  
MBD2 and MBD3 have both been described as subunits of the Mi-2/NuRD complex. 
It has been proposed that MBD2, which exhibits methyl CpG binding activity, serves 
to recruit the MBD3-containing Mi-2/NuRD complex to methylated promoters (16). 
Knock-out studies in mouse however suggest that MBD2 and MBD3 have distinct 
non-overlapping functions; whereas knocking-out MBD3 results in embryonic 
lethality, MBD2 knock-out mice are viable and display relatively subtle defects (18). 
Interestingly, Sansom and co-workers recently showed that the absence of MBD2 
protects against intestinal tumorigenesis (19). Thus, although biochemical evidence 
suggests that MBD2 and MBD3 are part of the same complex, the knock-out studies 
suggest that both proteins have specific or maybe partially overlapping functions.
To gain insights into the protein composition and function of MBD2 and MBD3 we 
generated stable cell lines expressing tagged versions of these proteins. Purification of 
the protein complexes revealed that MBD2 and MBD3 are not co-purifying but are 
mutually exclusive. In addition to known Mi-2/NuRD subunits, a 12 kD protein called 
DOC-1, was identified as a novel core subunit of both the MBD3 and MBD2 complex. 
Furthermore, PRMT5 and its associated co-factor MEP50, were found to co-purify 
with and methylate MBD2 in vitro. Finally, PRMT5 and its H4R3 histone 
methyltransferase activity were shown to be recruited with MBD2 to CpG islands in a 
methylation sensitive manner in vivo, suggesting an unexpected role for an arginine 
methyltransferase in repression by MBD2. Collectively, these findings provide 
evidence that MBD2/NuRD and MBD3/NuRD define two distinct protein complexes 
with different biochemical and functional properties.
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Materials and methods  
Constructs:
Oligos pRAV-myc1f and pRAV-myc1r encoding a myc epitope with EcoRI 
overhangs were cloned into EcoRI digested vector fragments of pRAV-FLAG (20) to 
generate pRAV-myc. An EcoRI/BamHI fragment from this vector containing one 
ProtA domain, two TEV cleavage sites and a myc epitope was then ligated with 
EcoRI/BamHI digested vector pZ-1-N(cellzome) to generate retroviral vector PZXN. 
MBD3, MBD2 and MBD2-RG lacking were PCR amplified with EcoRI and XhoI 
overhangs from MBD3 plasmid (RZPD) and an MBD2 plasmid (image clone 
collection) which were then ligated into EcoRI/XhoI digested vector pZXN.
To create a Strep-tagII (2TEV) myc 2xHA cassette, the (2TEV) myc cassette from 
PZXN was PCR amplified using a forward primer containing an EcoRI site and a 
Strep-tagII epitope and a reverse primer with an EcoRI overhang and two HA sites. 
This fragment was ligated into EcoRI digested vector psg5-HA TBP. The cassette was 
PCR amplified again with a forward primer containing a BamHI restriction site and a 
reverse primer containing one new HA epitope and a NotI restriction site. This PCR 
product was digested with BamHI and NotI and ligated into BamHI/NotI digested 
plasmid pcDNA5/FRT/TO/C-TAP (Kind gift from Bernard Luscher) to generate 
pcDNA5/FRT/TO/stII(2TEV)myc tripleHA. MBD2 was PCR amplified using primers 
containing NotI and Xho1 restriction sites and ligated into the NotI and XhoI site of 
pcDNA5/FRT/TO/stII(2TEV)myc tripleHA.  
A fragment encoding part of the RG stretch of MBD2 (EGARGGGRGRGR) 
containing BamHI and EcoRI overhangs was cloned in plasmid pGEX2T (Amersham 
Pharmacia Biotech). Full length MBD2, MBD RG lacking and MBD3 were PCR 
amplified with primers containing BamHI and EcoRI overhangs and cloned in 
BamH1/EcoR1 digested pGEX2T. Primers sequences are available upon request. 
Cell culture and stable cell lines: 
MCF7, HEK 293, HeLa, Phoenix and 293 FLP cells were maintained in Dulbecco’s 
modified Eagles’s medium (DMEM) (InVitrogen) supplemented with 10% fetal calf 
serum, 100 Pg of penicillin per ml and 100U of streptomycin per ml (InVitrogen) at 
37qC in 5% CO2. For AzaDc treatment MCF7 cells were seeded at low density and 
treated with 1PM of 5-aza-2'-deoxycytosine for 72h. Retroviral stable cell lines were 
generated according to this procedure: Phoenix amphotropic packaging cells (2.5 * 
106 cells) were seeded on a 9 cm dish and transfected 24 hours later with 20Pg of 
retroviral plasmid pZXN-MBD2a or pZXN-MBD2-RG lacking or pZXN-MBD3 
using the calcium phosphate method. After 48 hours virus containing supernatant was 
filtered through a 0.22-Pm-pore-size-filter. 105 Hela or 293 cells (105) were seeded  in 
a 6 well plate and transduced with 3ml filtered virus supernatant in the presence of 
8Pg/ml of polybrene for two infectious rounds of 24 hours. Cells were then incubated 
for 24 hours in normal media. The polyclonal population of cells was then selected 
with 1Pg/ml of puromycin. Clones were then selected, grown in isolation and 
screened for recombinant protein expression.  
A double stable cell line expressing tagged MBD2 and MBD3 was generated 
according to the following procedure: 293 FLP cells were transfected using the 
calcium phosphate method on a 9 cm dish with 2ug of 
pcDNA5/FRT/TO/stII(2TEV)myc tripleHA-MBD2 and 18ug of POG44. After 36 
hours cells were selected with 100Pg/ml hygromycin. Subsequently, clones were 
derived and screened for recombinant protein expression and zeocin sensitivity. One 
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good clone was then transduced with virus containing PZXN-MBD3 and was double 
selected with 100Pg/ml hygromycin and 1Pg/ml of puromycin.  
Protein purification: 
Cell pellets were resuspended in lysisbuffer (420 mM KCl, 20% glycerol, 20 mM 
Hepes pH 7.9, 0.2 mM EDTA, 5 mM MgCl2, 0.1 % Triton X-100, 10 mM ȕ-
mercaptoethanol, 1 mM PMSF and complete protease inhibitors (Roche) and 
homogenized by 20 strokes with a type B pestle. Extracts were then incubated for one 
hour in a rotation wheel at 4 ºC to extract nuclear proteins. Lysates were subsequenly 
clarified by ultracentrifugation at 100.000 g. Whole cell extracts were aliquoted, snap 
freezed, and stored at -80º C until further usage.   
Whole cell extracts derived from TAP-tagged cell lines were diluted with 2 volumes 
binding buffer (150 mM NaCl, 20 mM Tris-HCl pH 8.0, 0.1% NP40, 1 mM DTT, 1 
mM PMSF and complete protease inhibitors (Roche) and then incubated with IgG 
sepharose beads (Pharmacia) for 2 hours at 4 ºC in a rotation wheel. Beads were then 
washed three times with 10 bead volumes of washbuffer (500 mM NaCl, 20 mM Tris-
HCl pH 8.0, 0.5% NP40, 1 mM DTT and 1 mM PMSF) and twice with 10 bead 
volumes of TEV cleavage buffer (150 mM NaCl, 20 mM Tris-HCl pH 8.0, 0.1%NP40, 
1 mM DTT and 0.5 mM EDTA). Beads were then resuspended in one bead volume 
TEV cleavage buffer containing TEV protease and incubated overnight at 4 ºC in a 
rotation wheel. TEV eluates were precleared with Protein A beads (Pharmacia) and 
then subjected to immunoprecipitation using Myc antibody (9E11). 
Immunoprecipitates were washed 3 times with 10 bead volumes of washbuffer and 
twice with 10 bead volumes of peptide elution buffer (100 mM KCl, 20% glycerol, 20 
mM Hepes KOH pH 7.9, 0.2 mM EDTA, 0.1% NP50, 5 mM DTT and 0.5 mM 
PMSF). Protein complexes were eluted from the beads by incubation in peptide 
elution buffer containing 2 mg/ml of Myc peptide at 28 ºC for 30 minutes in a 
thermoshaker. The elution step was carried out twice and both eluates were pooled.
Endogenous immunoprecipitation assays were performed with HeLa nuclear extract 
in similar stringency conditions as for the TAP tag procedure. Antibody used were 
MBD3 (IBL, Japan) and MBD2 #07-198 (upstate). 
Protein analysis by GeLC-MS/MS: 
Purified protein complexes were loaded on SDS PAGE gels and run briefly to get rid 
of detergent and excess of peptide used for the elution. The gel lane was then fixed, 
cut in small pieces and subsequently reduced and alkylated. Proteins were digested 
overnight with trypsin (Promega) and eluted from the gel with TFA. Peptide 
identification experiments were performed using a nano-HPLC Agillent 1100 
nanoflow system connected online to a 7-Tesla linear quadrupole ion trap-Fourier 
transform (LTQ-FT) mass spectrometer (Thermo Electron, Bremen, Germany) 
essentially as described (21) 
ChIP assay: 
MCF7 cells were crosslinked with 1% formaldehyde for 15 minutes at room 
temperature and chromatin was prepared as described (22,23) but excluding CsCl 
purification. Chromatin was sonicated to an average size of 500 basepairs. Chromatin 
derived from one million cells was used for each immunoprecipitation in incubation 
buffer ( 1% triton X-100, 150mM NaCl, , 1mM EDTA pH 8.0, 0.5mM EGTA pH 8.0, 
10mM Tris pH 8.0, 1mg/ml BSA and protease inhibitors). 4Pg of the following 
Chapter 5
109
antibodies were used for immunoprecipitations: PRMT5 12-303 (Upstate), MBD2 
IMG-147 (Imgenex), MBD3 (IBL, Japan), MTA2 PC656 (Oncogene), anti-dimethyl-
histone H4 (Arg3) (#07-213) (Upstate). After overnight incubation at 4qC
immunoprecipitates were washed twice with 0.1% SDS, 1% Triton X-100, 0.1% 
deoxycholate, 0.15 M NaCl, 1 mM EDTA, 10 mM Tris (pH 8.0), 0.5 mM EGTA; 
once with 0.1% SDS, 1% Triton X-100, 0.1% deoxycholate, 0.5 M NaCl, 1 mM 
EDTA, 10 mM Tris (pH 8.0), 0.5 mM EGTA; once with 0.25 M LiCl, 0.5% 
deoxycholate, 0.5% NP-40, 1 mM EDTA, 10 mM Tris (pH 8.0), 0.5 mM EGTA; 
twice with 1 mM EDTA, 10 mM Tris (pH 8.0), 0.5 mM EGTA. Immunocomplexes 
were eluted from the beads by adding 1% SDS, 0.1 M NaHCO3 followed by 
incubation at room temperature for 15 minutes. Protein-DNA crosslinks were 
reversed in 0.2 M NaCl at 65°C for 4 hr, after which DNA was isolated by phenol-
chloroform extraction. Real time quantitative PCR analyses were performed to assess 
recruitment of the proteins to specific sites. The relative occupancy was derived from 
the percentage recovery of a specific CpG islands against the percentage recovery of a 
control BMX region. Mean and standard deviation was then calculated from ChIP 
experiments performed from three independent chromatin isolations. 
In vitro methylation assay: 
Whole cell extracts derived from the MBD2 stable cell line or wild-type HEK 293 
cells were diluted with 3 volumes of IPP150 (150mM NaCl, 20mM Tris HCl pH 8.0, 
0.1% NP-40, 1 mM DTT and 1 mM PMSF) and incubated with IgG Sepharose beads 
for 2 hours at 4qC in a rotation wheel. Beads were washed 3 times with 10 beads 
volumes of IPP150 and then incubated with 1 bead volume of PRMT5 incubation 
buffer (20mM Hepes pH 7.6, 500mM NaCl, 1mM MgCl2) in the presence of 0.25PCi 
of [14C]S-Adenosyl-Methionine (SAM) (Amersham). GST-PAH2, GST-MBD2, GST-
MBD2 RG lacking, GST-MBD3 and GST-EGARGGGRGRGR were expressed and 
purified as described previously (24). These purified proteins were incubated in 
PRMT5 incubation buffer supplemented with 0.25PCi of [14C]S-Adenosyl-
Methionine(Amersham) in the presence of purified MBD2 complex or a purified 
Drosophila fraction highly enriched for PRMT5/MEP50/USP7(25). After 2 hours 
incubation at 30qC products were separated on a 12% SDS PAGE gel. The gel was 
then dried and exposed on a phosphoscreen(Biorad) to identify methylated proteins.  
Results
Purification of TAP tagged MBD2 and MBD3 
Human embryonic kidney (HEK 293) cells stably expressing tagged versions of 
MBD2 and MBD3 were generated to determine their subunit composition. Gel 
filtration analysis of whole cell extracts derived from these cell lines indicated that 
both proteins are present in high molecular weight fractions of approximately 1-1.5 
MDa (fig. 1A).
To assess whether the TAP tagged MBD purified complexes were enzymatically 
active we performed deacetylation assays on nucleosomal templates acetylated by the 
SAGA and NuA4 complex (26). Both MBD2 and MBD3 protein complexes displayed 
robust TSA sensitive deacetylation activity towards histone H3 and histone H4 (fig. 
1B). To further investigate the functionality of the purified complexes, 
EMSA(electrophoretic mobility shift assays) using methylated DNA probes were 
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performed which revealed that only the MBD2 complex was able to bind to 
methylated DNA. MBD3 shows no affinity for methylated DNA, despite the presence 
of a highly conserved MBD domain, as reported previously (27) (figure 1C, compare 
lane 2 and 4).
TAP-MBD3
























































Figure 1.  TAP-MBD2 and TAP-MBD3 assemble into a functional Mi-2/NuRD like complex. (A) 
Superose 6 gel filtration of whole cell extracts derived from stable cell lines expressing TAP-MBD2 or 
TAP-MBD3. Fractions were analyzed by western blotting using a ProtA antibody. The void of the 
column is indicated between fraction 7 and 8. (B) Nucleosomal templates reconstituted with 
recombinant histones were acetylated by the S. cerevisiae SAGA or NuA4 complex and subsequently 
incubated with the TAP-MBD2 or TAP-MBD3 complex in the absence or presence of TSA (26). The 
amount of H3 or H4 acetylation was determined by Western blotting using antibodies against di-
acetylated histone H3 Lys 9,14 or tetra-acetylated H4, respectively. The binding of the MBD2 and 
MBD3 complex to the nucleosomal templates was determined by western blotting using a Myc and 
HDAC2 antibody. (C) EMSA assays using purified MBD2 and MBD3 complex were performed on the 
GAM12 probe as described (15). Shifted methylated probe is indicated with an arrow. Free probe is 
indicated with an asterisk.   
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MBD2 and MBD3 are mutually exclusive 
Previous studies have reported that MBD2 and MBD3 are part of the same complex 
(14). Silver staining of the purified MBD2 and MBD3 complexes revealed a protein 
of approximately 35 kD that is lacking in the MBD2 preparation (figure 2a, marked 
with an arrow). Western blotting identified this protein as MBD3 and revealed the 
absence of MBD3 in the MBD2 complex (figure 2B, compare lane 1 and 2). The 
absence of MBD3 in the MBD2 preparation cannot be explained by a shortage of 
endogenous MBD3 in 293 cells (figure 2B, lane 3). These data suggest that MBD2 






































































































Figure 2. MBD2 and MBD3 are mutually exclusive. (A) Silver stained gel of purified MBD2 and 
MBD3 complexes from HEK 293 cells. MBD3 is indicated with an arrow (B) Purified TAP-MBD2 
and TAP-MBD3 complex as well as whole cell extracts derived from HEK 293 or HeLa cells were 
analysed by western blotting using an MBD3 antibody. (C) Immunoprecipitation of MBD2 and MBD3 
using strep-tactin- or IgG beads, respectively. Lane (1) Strep purification on stII-3HA-MBD2 ProtA-
Myc-MBD3 extract (2) Strep purification on HEK 293 wild-type extract (3) IgG purification on stII-
3HA-MBD2 ProtA-Myc-MBD3 extract (4) IgG purification on HEK 293 wild-type extract (5) Input 
HEK 293 extract (6) Input stII-3HA-MBD2 ProtA-Myc-MBD3 extract. Eluted proteins were analysed 
by western blotting using an HA or ProtA antibody. Probing the blot with an HDAC1 antibody reveals 
co-precipitation of HDAC1 with MBD2 and MBD3. (C) Immunoprecipitation of endogenous MBD2 
and MDB3. Whole cell extract from HeLa cells were subjected to immunoprecipitation using antibodie 
against MBD3 (IBL, Japan) or MBD2 (upstate). Western blotting was performed using the same 
antibodies. 
If MBD2 and MBD3 are however present as a heterodimer in the Mi-2/NuRD 
complex, overexpression of one of the MBDs could cause a shift from a 
MBD2/MBD3 heterodimer population to a MBD2/MBD2 or MBD3/MBD3 
homodimer population. To assess this possibility we generated a stable cell line 
expressing MBD2 and MBD3 with different tag combinations. MBD3 was tagged 
with a ProtA domain and a Myc epitope, whereas MBD2 was tagged with a Strep tag 
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II and an HA epitope. Western blotting shows that both of these proteins are 
expressed in the stable cell line (figure 2C, lane 6). Purification of ProtA-Myc-MBD3 
on IgG beads resulted in purification of MBD3 (figure 2C, lane 3); tagged MBD2 
could not be detected in the immunoprecipitate. Similarly, purification of Strep TagII-
HA-MBD2a on streptactin beads resulted in purification of MBD2, whereas ProtA-
Myc-MBD3 did not co-purify (figure 2C, lane 1). HDAC1 co-purified with tagged 
MBD2 as well as MBD3, indicating that both tagged proteins assemble in a functional 
complex.  To further substantiate these observations immunoprecipitation 
experiments against endogenous MBD2 and MBD3 in HeLa cells were performed 
(fig. 2D). Immunoprecipitation of MBD2 resulted in purification of MBD2 but not of 
MBD3. Similarly, immunoprecipitation of MBD3 resulted in purification of two 
polypeptides whereas MBD2 did not co-purify. Based on their relative migration we 
presume these two polypeptides to be MBD3 and the smaller variant MBD3L2 
lacking the MBD domain. Collectively these experiments strongly suggest that MBD2 
and MBD3 are mutually exclusive. 
FT-MS/MS analysis of the purified MBD2 and MBD3 complex 
To further characterize the purified MBD2 and MBD3 complex LC FT-ICR MS 
analyses were performed (table 1). In agreement with the results described above, the 
MBD2 complex did not contain MBD3 and vice versa, corroborating and extending 
our conclusion that MBD2 and MBD3 are mutually exclusive in 293 cells. To 
unambiguously determine whether the observed mutual exclusiveness of MBD2 and 
MBD3 is specific for 293 cells or whether this is also true in other cells, a HeLa cell 
line stably expressing tagged MBD3 was generated. Purification of MBD3 from this 
cell line resulted in the purification of a Mi-2/NuRD complex lacking MBD2 
indicating that in HeLa cells MBD2 and MBD3 are also mutually exclusive 
(unpublished data).
In 293 cells, Mi-2D and Mi-2E were identified in both the MBD2 and MBD3 complex. 
These proteins have previously been characterized by the Schreiber lab as Mi-
2/NuRD components CHD3 and CHD4, respectively (28). At present we do not know 
whether these two isoforms are forming heterodimers or whether Mi-2D and Mi-2E
are assembled into distinct complexes. In both complexes, RbAp48 and -46 and 
HDAC1 and -2, the catalytic module for nucleosomal deacetylation activity, were 
identified. Furthermore, the highly related p66D and p66E proteins were identified in 
both complexes as described previously (29). We did not identify peptides matching 
the histone demethylase, LSD1, which has been reported to interact with the Mi-
2/NuRD complex (30). A 12 kDa protein called cdk2 associated protein 1 was 
identified as a novel Mi-2/NuRD component of both the MBD2 and MBD3 
complexes. Cdk2 associated protein 1 or DOC-1 (deleted in oral cancer-1) is a 
putative tumor suppressor reported to be inactivated during oral carcinogenesis and 
colon cancer (31,32). Furthermore the MBD2 but not the MBD3 eluate contained a 
large number of peptides matching the arginine methyltransferase PRMT5 as well as 
its associated protein called MEP50. Finally, several peptides matching different 
importin D nuclear transport proteins were identified. These proteins were absent in 
the MBD3 complex suggesting a specific interaction with MBD2. The association 
between MBD2 and importins may indicate that MBD2 shuttles between the 
cytoplasm and the nucleus. 
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Table 1: FT-MS/MS analysis of the purified MBD2 and MBD3 complex.  
 MBD2 purification        
(HEK 293) 
MBD3 purification         
(HEK 293) 
     








Mi-2 CHD4 163 50 123 43 
Mi-2 CHD3 65 25 48 22 
MTA1 72 60 39 44 
MTA1 variant 54 61 28 48 
MTA2 29 65 42 56 
MTA3 46 51 28 36 
MTA3 splicing variant 21 57 16 49 
P66 alpha 41 55 42 59 
P66 beta 57 65 44 58 
HDAC1 40 50 22 35 
HDAC2 49 44 35 45 
RbAp46 22 41 18 34 
RbAp48 18 37 17 43 
DOC-1 3 36 3 36 
MBD3 - - 18 41 
MBD2a 35 58 - - 
PRMT5 18 30 - - 
MEP50 7 21 - - 
Importin Į-6 subunit 3 6 - - 
Importin Į-5 subunit 3 5 - - 
Importin Į-4 subunit 5 7 - - 
     
Strikingly all three MTA proteins MTA1, -2 and -3 as well as two MTA splice 
variants were identified in the MBD2 and MBD3 complex (table 1). It has been 
suggested that MTA proteins display tissue-specific differential expression giving rise 
to distinct Mi-2/NuRD complexes (16,33-35). Surprisingly, a large number of 
different post-translational modifications were identified in all major NuRD subunits 
(supplementary table 1). A previous study characterized phosphorylation sites in Mi-
2Į, Mi-2ȕ, p66D, p66E, HDAC1 and HDAC2 (36). We confirmed the presence of 
these phosphorylation sites in the NuRD complex and in addition identified a plethora 
of new sites in the latter as well as in MBD2, MTA1, MTA2 and MTA3. Several post 
translational modifications were detected in conserved domains and these might 
therefore have a role in regulating protein-protein or protein-DNA interactions or in 
fine tuning of enzymatic activities. Furthermore ~90% of these modifications 
occurred in highly conserved residues supporting a role for these modifications 
throughout evolution.
PRMT5 associates with and symmetrically di-methylates MBD2.
PRMT5 was detected by FT-MS/MS in the MBD2 complex but was absent from the 
MBD3 peptide eluate which was confirmed by western blotting (fig. 3A). Inspection 
of the amino acid sequence of the subunits of the MBD2 complex revealed that 
MBD2 has a long stretch of RG repeats N-terminal to the MBD domain (fig. 3B), 
whereas RG repeats are not present in MBD3 or in other subunits. Since the RG motif 
is a substrate for PRMT5 (37), we tested whether the MBD2 RG stretch is a substrate 
for PRMT5.

















































































































































Figure 3. PRMT5 interacts with and methylates the N-terminal RG rich repeat of MBD2. (A) Purified 
TAP-MBD2 and TAP-MBD3 complex were analysed by western blotting using a PRMT5 antibody. (B) 
Sequence of MBD2 with the RG repeats being underlined. (C) In vitro methylation of purified MBD2 
complex upon incubation with [14C] S-Adenosyl Methionine. Methylated protein is indicated with an 
arrow. Free label is indicated with an asterisk. MBD2 complex was purified using Igg beads. Left panel 
depict a western blot analysis of the purified MBD2 complex or a 293 control purification using D-
protA-HRP antibody. Arrow shows Tap-tagged MBD2.(D) (left panels) In vitro methylation of 
recombinant GST-RG(n) and GST-MBD2 in the presence of [14C] S-Adenosyl Methionine and a 
purified PRMT5/MEP50 fraction (middle panel) or the purified MBD2 complex (top panel). GST-
PAH2 was used as a negative control. (right panels) In vitro methylation of recombinant GST-RG(n), 
GST-MBD2 RG lacking and GST-MBD3 in the presence of [14C] S-Adenosyl Methionine and a 
purified PRMT5/MEP50 fraction (middle panel) or the purified MBD2 complex (top panel). Free label 
is indicated with an asterisk. Loading control for GST-PAH2, GST-RG(n), GST-MBD2, GST MBD2 
RG lacking and GST-MBD3 are shown in the bottom panels.. (E) Silver stained gel of purified N-
terminally truncated MBD2 complex from HEK 293 cells. The table shows the FT-MS/MS analysis 
with all identified proteins and their respective peptide numbers and percentage sequence coverage.  
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Incubating purified MBD2 complex in the presence of [14C] S-Adenosyl-methionine 
resulted in a single radioactive band migrating at the position of Tap-tagged MBD2 in 
the gel (fig. 3C). To substantiate these observations we fused full length MBD2 or the 
RG stretch of MBD2 to GST and tested whether the purified MBD2 complex 
containing PRMT5 could methylate these fusion proteins. As shown in the left panel 
in figure 3D, the MBD2 complex was able to specifically methylate these 
recombinant substrates but not a GST-PAH2 control. To evaluate whether PRMT5 
specifically methylates the RG stretch of MBD2, MBD2 lacking the RG stretch or 
MBD3 were fused to GST and incubated with purified MBD2 complex. As shown in 
the right panel in figure 4D, the MBD2 complex was able to specifically methylate 
the RG stretch of MBD2 but not MBD3 or MBD2 lacking the RG stretch. A control 
for the methylation reaction using a purified PRMT5 containing fraction from 
Drosophila displayed similar activity as compared to the MBD2 complex, thus 
confirming the specificity of PRMT5 in this assay. In addition, a search for post-
translationally modified peptides in the FT-MS/MS run of the purified MBD2 
complex indeed revealed a peptide containing three di-methyl arginine residues 
(supplementary table 1). Taken together, these experiments strongly suggest that 
PRMT5 methylates MBD2 on several arginine residues located in the RG-rich amino 
acid stretch immediately upstream of the MBD domain of MBD2 in vitro.
To investigate whether the RG stretch of MBD2 is required for the interaction 
between PRMT5 and the MBD2 complex, we generated a stable cell line expressing a 
truncated MBD2 protein starting at the second methionine in the MBD2 sequence, 
thus lacking the RG stretch. Following purification and FT-MS/MS analysis, Mi-
2/NuRD components, the novel core subunit DOC-1 as well as importin D proteins 
were present. However, peptides matching to either PRMT5 or MEP50 were not 
identified (fig. 3E). Western blotting confirmed that PRMT5 was present in crude 
extracts but absent in the truncated MBD2 eluate (data not shown). Taken together 
these results strongly suggests that PRMT5 interacts with the N-terminal RG rich 
stretch of MBD2 and methylate this RG stretch.
PRMT5 is recruited to chromatin by MBD2 
To assess whether PRMT5 plays a role on chromatin with MBD2, we performed 
chromatin immunoprecipitation experiments on endogenous proteins in MCF7 breast 
carcinoma cells. Different CpG island targets which were previously shown to be 
methylated and bound by MBD proteins in MCF7 cells were analyzed (38-40) (figure 
4A). Chromatin immunoprecipitation using MTA2, MBD2 and MBD3 antibodies 
followed by real time quantitative PCR analysis revealed the recruitment of these 
proteins to two CpG islands, one located close to the first exon of P14ARF and a 
second CpG island located before the first exon of P16INK4a (fig. 4B). Several other 
tested CpG islands did not recruit MTA2, MBD2 and MBD3. Next, we performed 
chromatin IPs using an antibody against PRMT5 and this revealed the recruitment of 
PRMT5 to the P14ARF and P16INK4a CpG islands . These results provide a functional 
link between MBD2 and the arginine methyltransferase PRMT5 in vivo.
The biochemical experiments described in this study revealed that MBD2 and MBD3 
are mutually exclusive and that PRMT5 interacts with MBD2 but not with MBD3. 
The ChIP experiments indicate that MBD2, PRMT5 as well as MBD3 are recruited to 
the P14ARF and P16INK4a CpG islands. To investigate whether the recruitment of 
MBD2, PRMT5 and MBD3 to these loci was dependent on CpG methylation, we 
treated MCF-7 cells with AzadC, a specific inhibitor of DNA methylation, and 
subsequently investigated the recruitment of MBD2, MBD3, PRMT5 and MTA2 to  


















Figure 4. MBD2 recruits PRMT5 to chromatin (A) Schematic representation of the primer sets used in 
the ChIP experiments. Exons are indicated with black rectangles. CpG islands are indicated in grey. 
Primer pairs are indicated with arrows. (B) ChIP analysis of MBD2, MBD3, PRMT5 and MTA2 in 
MCF7 cells. Relative occupancy over a control BMX region are shown. Values are the means with S.D. 
of the results from ChIP experiments from three independent chromatin isolations. (C) ChIP analysis of 
MCF7 cells treated with 5-azacytidine. Immunoprecipitation were performed with antibodies against 
MBD2, MBD3, MTA2, PRMT5 and anti-dimethyl-histone H4 (Arg3). Relative occupancy over a 
control BMX region are shown. Values are the means with S.D. of the results from ChIP experiments 
from three independent chromatin isolations. 
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the P14ARF and P16INK4a CpG islands. As shown in figure 4C, AzadC treatment 
resulted in a significant loss of MBD2 binding. Strikingly, a reduction of PRMT5 
binding to the loci could be observed, indicating that MBD2 and PRMT5 are binding 
to the P14ARF and P16INK4a CpG islands in a methylation sensitive manner. In contrast, 
recruitment of MBD3 to these loci was only moderately affected. MTA2, a protein 
present in both the MBD2 and MBD3 complex was reduced with about 50 percent. 
Thus, MBD2 and PRMT5 are recruited to the CpG islands in a methylation dependent 
manner, whereas MBD3 is only partially affected, supporting the notion that 
MBD2/PRMT5 and MBD3 are at least to some extent assembling on the CpG islands 
as distinct complexes. PRMT5 recruitment to promoters  is known to correlate with 
arginine methylation of histones (41). To investigate whether PRMT5 recruitment to 
the P14ARF and P16INK4a CpG islands correlates with arginine methylation of histone 
H4 we performed chromatin immunoprecipitation experiments assay on MCF7 cells 
treated with or without AzadC using an antibody against dimethylated histone H4R3. 
As shown in figure 4C recruitment of PRMT5 to the P14ARF and P16INK4a CpG islands 
correlates with an enrichment in the level of arginine di-methylated histone H4R3. 
Strikingly, treatment of MCF7 cells with AzadC resulted in a reduction of the level of 
di-methylated histone H4R3. Thus PRMT5 recruitment to the P14ARF and P16INK4a
CpG islands correlates with histone H4R3 methylation. 
In conclusion the experiments described in this study indicate that MBD2 and MBD3 
assemble in distinct Mi-2/NuRD like complexes and are mutually exclusive. 
Furthermore, PRMT5 binds to and methylates MBD2 and is recruited together with 
an MBD2 containing Mi-2/NuRD complex to CpG islands in a methylation dependent 
manner in vivo.
Discussion
In this study we set out to gain insights into the function of MBD2 and MBD3. We 
applied a protein tagging approach to purify MBD2 and MBD3 complexes from 
mammalian cells. Strikingly, although these proteins have been described to be part of 
the same complex, we found them to reside in distinct complexes. MBD2 could not be 
detected in the purified MBD3 complex and vice versa. Independent purification of 
MBD2 and MBD3 from a double stable cell line expressing MBD2 and MBD3 with 
different tags to similar levels confirmed their mutual exclusiveness. In addition, 
endogenous MBD2 did not immunoprecipitate MBD3 and vice versa. Finally, MBD2 
could also not be detected in an MBD3 complex purified from HeLa cells stably 
expressing tagged MBD3 (supplementary figure 1). Feng and Zhang used 
conventional chromatography to purify the MBD2-containing MeCP1 complex from 
HeLa nuclear extracts and found MBD3 to co-purify, and argued that these proteins 
are indeed part of the same complex (14). However, this purified fraction may in fact 
be a mixture of Mi-2/NuRD complexes, some containing MBD2 and others MBD3. 
As they likely have a very similar binding affinity for the different chromatographic 
resins they would end up in the same fractions throughout the purifications. Jiang and 
co-workers performed yeast-two-hybrid assays and GST pulldowns and found MBD2 
and MBD3 to interact directly (42). Although we can not exclude that a small fraction 
of free MBD2 and MBD3, if existing in the cell tested, are interacting, our 
experiments clearly show that the vast majority of MBD2 and MBD3 independently 
assemble in distinct Mi-2/NuRD like complexes, which we propose to call 
MBD2/NuRD and MBD3/NuRD. Based on the different subunit composition in 
particular the presence of PRMT5, MEP50 and the importin complex in MBD2 but 
MBD2/NuRD and MBD3/NuRD two distinct complexes with different biochemical                
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not MBD3 we hypothesize that these complexes have different functions inside the 
cell. This hypothesis is supported by the AzadC ChIP experiments described in figure 
4 showing a methylation dependent MBD2/PRMT5 recruitment to the P14ARF and 
P16INK4a CpG islands whereas MBD3 recruitment to these loci is largely independent 
of methylation.  
PRMT5 and the Mi-2/NuRD complex 
LC-MS/MS and western blot analyses revealed the association of the arginine 
methyltransferase PRMT5 and its associated protein MEP50 with the MBD2/NuRD 
complex, whereas these proteins were lacking in the MBD3/NuRD complex. Whether 
PRMT5 is a core subunit of the MBD2/NuRD complex or a protein strongly 
interacting with the MBD2/NuRD complex remains to be determined. PRMT5 is 
recruited to the MBD2/NuRD complex via the RG-rich N-terminus of MBD2. In 
addition we provided evidence that PRMT5 can methylate this RG stretch of MBD2. 
Therefore, we hypothesize the RG stretch of MBD2 might serve a dual purpose as a 
substrate and as a docking site for PRMT5. PRMT5 has been shown to function in 
repression of tumor suppressor genes, presumably by adding repressive arginine 
methyl marks to the histone H3 and H4 tails (43). In agreement with this we found 
PRMT5 to co-localize with MBD2 on P14ARF and P16INK4a CpG islands and this 
correlates with histone H4R3 dimethylation, thus providing a functional link between 
PRMT5 and MBD2 in vivo.
Mi-2/NuRD, a family of protein complexes: 
Since its first description some 7 years ago, the Mi-2/NuRD complex has generally 
been regarded as one biochemical entity containing a number of core polypeptides. 
However, our study clearly reveals the presence of MBD2/NuRd and MBD3/NuRD 
complexes with distinct subunit compositions. Previous observations from a number 
of labs have revealed the existence of additional Mi-2/NuRD complexes defined for 
example by different MTA variants, which may allow for a further fine tuning of 
different Mi-2/NuRD complexes (16,33-35,44). Finally, in addition to altering protein 
composition, post-translational modifications of different Mi-2/NuRD subunits 
(supplementary table 1) also may play an important role in regulating its function.  
The results described in this study lead us to propose a feed forward mechanism of 
repression by different Mi-2/NuRD complexes. The different enzymatic activities 
gathered within a single protein complex may act synergistically to regulate 
repression of MBD2 target genes: Deacetylation of nucleosomes surrounding the 
targeting site in combination with the addition of transcriptional repressive arginine 
methyl marks in the H4 tail by the associated PRMT5 (43). Furthermore, chromatin 
remodeling catalyzed by the ATPase Mi-2 may occur. The hypoacetylated and 
arginine methylated nucleosomes surrounding the MBD2/PRMT5 targeting site in 
turn may provide a binding scaffold for the MBD3/NuRD complex, a complex which 
has a high affinity for hypoacetylated nucleosomes (data not shown). This results in 
the co-occurrence of the MBD2/NuRD and MBD3/NuRD complexes on some CpG 
islands. Further deacetylation of nucleosomes by the MBD3/NuRD complex can then 
facilitate spreading of deacetylation and maintenance of transcriptional repression. 
Unraveling the functions unique to each Mi-2/NuRD complex is a challenging task 
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Transcription in eukaryotic cells occurs in a chromatin setting and is strongly 
influenced by covalent modifications of core nucleosomal histones. One of these 
modifications, histone acetylation, involves recruitment of histone acetyl transferases 
(HAT) complexes and is associated with increased transcriptional activity. 
Conversely, histone hypoacetylation involves recruitment of histone deacetylases 
(HDAC) complexes and is associated with repression of transcription. Although 
discovered a decade ago, HDAC containing complexes remain poorly understood 
with respect to their mechanism of transcriptional repression. In the studies described 
in this thesis new molecular insights are provided for two major class I HDAC 
containing complexes: Sin3 and Mi-2/NuRD. First, we established the structural 
specificity of the recruitment of the tumor suppressor Mad to the PAH2 (paired 
amphipatic helix) domains of Sin3b using a gain and loss of function approach 
(chapter 3). To assess the sequence motif requirements for the PAH1 and PAH2 
domain of Sin3, a yeast two hybrid screen was performed and PAH1 and PAH2 
interacting peptides were identified. Additionally mSin3b complex was purified and 
characterized using a new tagging/proteomic approach (chapter 4). Finally, a TAP 
tagging approach in mammalian cells using MBD2 and MBD3 revealed new Mi-
2/NuRD complexes with distinct biochemical compositions and functions (chapter 5). 
These new findings and their implications for future research will be discussed.  
The PAH1 and PAH2 domains of mSin3b, two scaffolds with distinct specificity.  
Chapter 3 provides a molecular basis for the specificity of interaction of the N-
terminus of Mad to the PAH2 domain of mSin3b. Using molecular modeling of PAH1 
and superposition of the PAH1 model with the structure of PAH2 including the Mad 
SID pinpointed to Glu-6, Phe-7, Ile-11, Val-14, Asn-15, Ile-17, Arg-29, Leu-35, His-
36, and Gln-39 as potential PAH2 selective residues. We then performed a gain-of-
function approach in the PAH1 domain by exchanging every amino acid with the 
potential PAH2 selective modifiers. We revealed a critical role for Phe7 and a 
stabilizing role for Val14 and Gln39 in establishing an interaction with Mad SID at 
the PAH1 domain. To extend and corroborate our findings we performed a loss-of-
function analysis in the PAH2 domain by exchanging Phe7, Val14 and Gln39 with the 
amino acid present at the respective position in the PAH1 domain and could confirm 
that Phe7 is a critical amino for the interaction with Mad whilst Val14 and Gln39 play 
a stabilizing role. We hypothesize two aromatic residues Phe7 in PAH2 and Tyr18 in 
the Mad-SID to be the key to the complex formation between PAH2 and Mad. 
Interaction between aromatic residues has been reported to be important for many 
other protein structure [1]. A stacking interaction between the two aromatic rings of 
these residues could potentially provide the required free energy to establish an 
interaction between Mad and the PAH2 domain of mSin3b. Parallel to our studies 
Cowley et al made an interesting observation with the PAH1 and the PAH2 domain in 
mSin3a isoform [2]. Using GST pulldown assays they showed that fragments 
containing both PAH1 and PAH2 interact stronger with Mad than the PAH2 domain 
alone. Introducing proline in PAH1 reduced the binding of Mad to this fragment 
which led the authors to suggest that PAH1 interacts with PAH2 for cooperatively 
binding to Mad. We provided biochemical evidence in vitro and showed that PAH1 
was directly contacting Mad in pulldown experiment. In a competitive setting 
between PAH1 and PAH2 the interaction of Mad with PAH1 could be reduced using 
decreasing amounts of Mad. Therefore, we favor a model in which Mad has a weak 
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affinity for PAH1. Whether such phenomena take place in vivo remains to be 
investigated. 
Although we provide evidence that introduction of Phe7, Val14 and Gln39 in PAH1 
can establish an interaction with Mad in vivo using a yeast two hybrid system and in 
vitro in pulldown assays, an interesting confirmation and extension of our results 
could involve immunoprecipitation of the endogenous Mad/Sin3b/HDAC complex 
level using full length mSin3b with inverted specificity at the PAH1 and PAH2 
domains in combination with a negative control which would consist of full length 
mSin3b mutated at the PAH2 domain.  
In chapter 4, we identified peptides interacting with the PAH1 and PAH2 domain of 
mSin3b by performing a yeast two hybrid screen using a peptide aptamer library. 
Interestingly, mutation of PAH1 or PAH2 residue 7, 14 and 39 affected binding of the 
identified peptide aptamers. Replacing Phe7 with Val7 in PAH2 abolished the 
interaction with PAH2 interacting aptamers, extending the important role of the 
interaction of Phe7 of PAH2 with Mad to possibly other SID interacting proteins. 
Introduction of Val14 and Gln39 in PAH1 decreased the interaction of PAH1 with 
aptamers containing an LVXLL motif. We previously showed that Val14 and Gln39 
in PAH2 were stabilizing residues for Mad association with PAH2. We therefore 
suggest that residues 7, 14 and 39 in PAH1 and PAH2 play a determining role in the 
specificity of interactions between PAH1 and PAH2 and their respective interacting 
partners (fig. 1).
We identified two PAH1 aptamers with a LVXLL sequence that is very similar to the 
LXXLL motif in the coactivators of nuclear hormone receptor. Despite this 
homology, PAH1 identified aptamers were in general not present in nuclear proteins 
due to overrepresentation of rare hydrophobic residues such as tryptophans and 
phenylalanine, illustrating the limitation of the aptamer approach which selects for 
random peptides. Three PAH2 identified aptamers can be aligned with previously 
identified interacting proteins such as Ume6, HBP1 and Kruppel like family members 
while one aptamer has a striking homology to the Mad-SID. The identification of two 
PAH2 aptamers groups suggests that PAH2 can accommodate several motifs. 
Additionally, in view of the work of Swanson and coworkers which showed that 
HBP1 SID interacts with the PAH2 domain in a reverse orientation of the Mad-SID 
we propose HBP1 homolog aptamers to interact with PAH2 in a reverse orientation of 
the Mad-SID like aptamer (fig. 1) [3].  
We purified the mSin3b complex using a new tagging/proteomic approach. Apart 
from known core components of the Sin3/HDAC complex, this approach revealed 
several transcription factors including Mad, Pf1 and a novel protein, Neural retina 
leucine zipper (NRL). Strikingly, one identified PAH2 aptamer had a good sequence 
identity with the region 125-150 of NRL suggesting association of NRL with the 
PAH2 domain of mSin3b which was corroborated by GST pulldown experiments. 
Association between Sin3 and NRL is provocative in light of previous reports which 
showed that NRL was a transcriptional activator of the rhodopsin gene in retina. 
Interestingly, activation assay experiments have shown that a NRL fragment 
encompassing residues 1-125 has a higher reporter gene activity in comparison to full 
length NRL suggesting that recruitment of the Sin3/HDAC complex to the C-terminal 
part of NRL squelches its transactivation activity [4]. The association between NRL 




Figure 1. Overview of the molecular determinants of the PAH domains and their interacting partners. 
PAH1 predicted structure model is shown with a suggested specificity defined by Val7, Leu14 and 
Lys39 amino acids for recruiting LVXLL motif. We presume LVXLL sequences to form an D-helix 
from which the orientation in the PAH1 domain remains to be established. PAH2 best model of NMR 
structure is shown with a suggested specificity defined by Phe7, Val14 and Gln39 for recruiting Mad 
SID family members and AAXV[LA] SID. AAXV[LA] containing proteins are presumed to interact 
with the PAH2 domain in a reverse orientation of the Mad SID family members. An important 
characteristic for the high affinity between Mad and PAH2 could involve a stacking ring interaction 
between Mad-Tyr18 and PAH2-Phe7 residue. Interplay between PAH1 and PAH2 domain could play a 
role in the function of Sin3 and their interacting partners. 
Purification of MBD2 and MBD3 complex. 
TAP tagging purification is widely used in yeast, however a number of technical 
problems are encountered when using mammalian cells [5]. The calmodulin binding 
peptide is originally used as the final, second affinity step.  In mammalian cells, 
binding to calmodulin in the presence of calcium is hampered by the presence of 
many endogenous proteins that interact with calmodulin in a calcium-dependent 
manner. We adapted the yeast TAP-tagging approach to human cells by replacing the 
calmodulin with a myc immunoaffinity step. This approach was successfully used to 
purify MBD2 and MBD3 associated proteins. We show that MBD2 and MBD3 
assemble independently of one another into a Mi-NuRD-like functional complex in 
which all of the known core subunits are present. Although previously described to be 
part of the same complex, we revealed that MBD2 and MBD3 do not co-purify. To 
exclude the possibility that overexpression of one of the MBDs shift an MBD2/MBD3 
heterodimer population to a MBD2/MBD2 or MBD3/MBD3 homodimer population 
we established a stable cell line expressing both MBDs at similar levels.  Using 
different tag combination, we then purified MBD2 and MBD3 and confirmed their 
mutual exclusiveness. These results challenge previous reports. Using conventional 
chromatography approach, MBD2, MBD3 and Mi-2/NuRD subunits were reported to 




















hence would very likely have similar behaviors in chromatography and end up in the 
same or overlapping fractions throughout the purification.
Human MBD2 was reported to bind methylated DNA whereas human MBD3 
displayed no detectable methyl-DNA binding activity. It has been suggested that 
MBD2 serves to target the MBD3 complex to methylated promoters. However, we 
performed biochemical experiments and showed that MBD2 and MBD3 do not 
interact. Additionally, treatment of cells with an inhibitor of DNA methylation 
revealed a methylation-dependent recruitment of MBD2 to two CpG islands and a 
methylation-independent recruitment of MBD3, indicating that MBD2 binding to 
these loci is dispensable for MBD3. Given the fact that MBD3/NuRD complex shows 
high affinity for hypoacetylated nucleosomes (data not shown), we suggest a feed 
forward mechanism of repression mediated by the Mi-2/NuRD complexes: In an 
initial step, MBD2/NuRD complex binds to methylated CpG islands and causes 
deacetylation of nucleosomes surrounding the targeting site. These hypoacetylated 
nucleosomes in turn create a binding scaffold for the MBD3/NuRD complex resulting 
in strengthening of transcriptional repression and spreading of deacetylation.  
Another significant finding of our study is the identification of the arginine methyl 
transferase PRMT5 and its associated subunit MEP50 in the MBD2/NuRD complex. 
Furthermore, PRMT5 binds the N-terminus of MBD2 in vivo and methylates in vitro
the N-terminus of MBD2 rich in RG repeats. PRMT5 and MBD2 are recruited to 
methylated CpG islands of P14ARF and P16INK4A gene in a DNA methylation 
dependent manner. Interestingly, PRMT5 was shown in other studies to contribute to 
repression of transcription by methylating R8 and R3 on respectively Histone H3 and 
H4 suggesting a synergy between deacetylation, chromatin remodelling and protein 
arginine methyl transferase activity in gene silencing on methylated DNA [7]. 
Whether PRMT5 in the MBD2 complex also methylates the MBD2 RG stretch to 
regulate MBD2 binding to DNA or whether PRMT5 addditionally contributes to 
transcriptional repression via methylation of arginine residues in histone tails remains 
to be investigated.
To add yet another level of complexity, a perplexing large number of post-
translational modifications occur on MBD2/NuRD and MBD3/NuRD complex 
subunits, suggesting additional possibilities of regulation of these distinct complexes.  
This thesis provided many insights into the structure and mechanism of co-repressor 
complexes, and offers new challenges and questions. PAH1 structure and function in 
the Sin3 complex is still poorly characterized. Identification of PAH1 interacting 
proteins and resolving the NMR structure of their interaction with PAH1 will provide 
a structural basis for understanding the specificity of the PAH1 and PAH2 domains.  
HDAC inhibitors such as SAHA, TSA or VPA have a high potential as anti-leukemic 
drugs and are on clinical trials. Nevertheless these HDAC inhibitors have a broad 
range and side effects in the treatment of leukemia. Using peptide aptamers could be 
an interesting drug alternative due to their ability to block binding and therefore 
functions of proteins that recruit Sin3/HDAC in vivo [8]. Blocking of PAH1 or PAH2 
domain binding through aptamers or mimicking SID peptides would prevent 
recruitment of HDAC activity to a genomic locus. Such an approach would be more 
specific than classical HDAC inhibitors.
DOC-1 a putative tumor suppressor interacting with Mi-2/NuRD complex would be 
an interesting new subunit to characterize, as providing possibly a new way to block 
proliferation of cells [9]. DOC-1 was reported as well to interact with cdk2 suggesting 
possible involvement of Mi-2/NuRD complex in cell cycle regulation.  
Chapter 6
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High throughput technologies in genomics are emerging and will certainly allow 
chromatin profiling and identification of the genomic binding sites of class I HDAC 
containing complex and their subunits. The availability of the epigenome combined 
with proteomics data will reach a challenging complexity from which understanding 
of the functional role of co-repressor complexes in the regulation of transcription and 
disease will greatly benefit.
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In eukaryotes, DNA is packaged with histone proteins into a higher order structure 
termed chromatin. Post translational modifications occurring on histones play an 
important role in the modulation of this compact structure and in regulation of 
transcription. One of these modifications includes histone acetylation which largely 
correlates largely with transcriptional activation. The reverse reaction, histone 
deacetylation, is generally accepted to result in transcriptional repression. Histone 
acetylation and histone deacetylation are processes mediated by complexes containing 
histone acetyl transferases (HAT) or histone deacetylases (HDAC). Here, new 
molecular insights are presented for two class I HDACs containing complexes: Sin3 
and Mi-2/NuRD.
In chapter 1, we introduce biochemical and structural aspects of class I HDAC 
containing complexes. In chapter 2, we present a perspective on experimental trials 
used in this thesis. These include tandem affinity purification (TAP tagging), 
proteomics and chromatin immunoprecipitation (ChIP). In Chapter 3, we establish a 
gain and loss of interaction assay to reveal the critical amino acids which convey the 
interaction between the tumor suppressor Mad and the PAH2 domain of the mSin3b 
co-repressor. Introducing PAH2 residues contacted by Mad into the PAH1 domain of 
Sin3 revealed then a critical role for PAH2 residue Phe7 as well as a stabilizing role 
for PAH2 residues Val14 and Gln39 in the interaction between PAH2 and Mad. The 
reverse substitution of PAH2 residue Phe7, Val14 and Gln39 with their respective 
residue in PAH1 extended and corroborated their critical and stabilizing roles. Above 
all, we establish Phe7 as the most important amino acid for the interaction between 
Mad and Sin3.
In chapter 4, we identify peptides interacting with the PAH1 and PAH2 domain of 
mSin3b by performing a peptide aptamer screen in a yeast two hybrid setting (chapter 
4). Substitution in PAH2 of Phe7 and Val14 with their respective PAH1 residues 
affected PAH2 identified aptamers in a similar manner as Mad. Two PAH1 identified 
aptamers shared an LVXLL motif and were affected by substitution of Leu14 and 
Lys39 in PAH1 with their respective PAH2 residues. Our results suggest that amino 
acids 7, 14 and 39 define the specificity of the PAH1 and the PAH2 domain of Sin3 
co-repressor for recruitment of DNA binding repressors. Furthermore, using a new 
tagging/proteomic we purify the Sin3b co-repressor complex and reveal neural retina 
leucine zipper as a new Sin3 interacting protein. NRL shares a good sequence identity 
with one PAH2 aptamer and association between PAH2 and NRL is shown.
In chapter 5, we analyse the composition of MBD2 and MBD3 containing complexes 
using a new tagging approach. Surprisingly, we reveal that MBD2 and MBD3 
assemble into mutually distinct functional Mi-2/NuRD co-repressor complexes. We 
further observe co-purification of a novel core subunit DOC-1, a putative tumor 
suppressor.  The arginine methyl transferase PRMT5 is specifically associated with 
the MBD2/NuRD complex. We show that PRMT5 associates and methylates the N-
term region of MBD2 especially rich in RG repeats.  Furthermore, PRMT5 is 
associated in vivo with methylated CpG islands, together with MBD2 in a DNA 
methylation dependent manner. Our data suggests that Mi-2/NuRD comprises a 
family of protein complexes with distinct biochemical and functional properties. 
In conclusion, the work described in this thesis provides a clearer understanding of 
how the PAH1 and PAH2 domain of Sin3, establish an association with their 
interacting partners. The identification of new subunits in Mi-2/NuRD complex 
composition should hopefully provide the necessary ground to elucidate the 






In eukaryoten wordt DNA opgeslagen door middel van histonen in een structuur die 
chromatine wordt genoemd. Post-translationele modificaties van histonen spelen een 
belangrijke rol in de regulatie van deze compacte structuur en in de regulatie van 
transcriptie. Een van deze modificaties is acetylatie en deze modificatie correleert 
doorgaans met activatie van transcriptie. Omgekeerd wordt deacetylatie geassocieerd 
met transcriptionele repressie. Acetylatie van histonen wordt gereguleerd door 
eiwitcomplexen die histone acetyltransferases (HATs) of histone deacetylases 
(HDACs) bevatten. In dit proefschrift worden nieuwe moleculaire inzichten verschaft 
in twee eiwitcomplexes die histone deacetylase activiteit bevatten: Sin3 en Mi-
2/NuRD.
In hoofdstuk 1 worden de biochemische en structurele aspecten van histone 
deacetylase bevattende eiwitcomplexen uiteengezet. Hoofdstuk 2 geeft een overzicht 
van de experimentele toepassingen die in dit proefschrift aan de orde komen, 
waaronder Tandem Affiniteit Purificatie (TAP tagging), proteomics en chromatine 
immunoprecipitatie (ChIP). Hoofdstuk drie beschrijft een assay waarmee de 
aminozuren die van belang zijn voor de interactie tussen de tumor suppressor Mad en 
het PAH2 domein van Sin3B worden bepaald. Met behulp van substitutieproeven 
werd vastgesteld dat residue Phe7 van PAH2 bepalend is voor de interactie tussen 
Mad en PAH2. Verder zijn Val14 en Gln39 van belang voor additionele stabiliserende 
interacties. Deze bevindingen werden verder bevestigd door introduktie van deze 
aminozuren in PAH1; dit resulteerde namelijk in een specifieke interactie tussen Mad 
en PAH1. In hoofdstuk 4 wordt een yeast two-hybrid screening uitgevoerd om 
peptides die specifiek aan PAH1 en PAH2 binden te identificeren. Twee peptides die 
specifiek een interactie aangaan met PAH1 bevatten beide een LVXLL motief. De 
interactie tussen deze peptides en PAH1 werd verstoord door substitutie van Leu14 en 
Lys39 door de aminozuren die op deze posities voorkomen in PAH2. Deze resultaten 
tonen aan dat aminozuren 7, 14 en 39 in PAH1 en PAH2 belangrijke determinanten 
zijn voor de interactie tussen PAH1 en PAH2 en DNA bindende repressor moleculen. 
Verder wordt in dit hoofdstuk de zuivering en karakterisatie van het Sin3B complex 
door middel van TAP tagging beschreven. Deze analyse resulteerde in de 
karakerisatie van het eiwit NRL als een nieuwe Sin3B interactor. NRL bevat een 
motief dat ook voorkomt in een van de peptides die in de yeast two hybrid screening 
werd geidentificeerd als een PAH2 interactor. Met behulp van een in vitro assay werd 
vervolgens een specifieke interactie tussen NRL en PAH2 aangetoond. Hoofdstuk 5 
beschrijft de karakterisatie van het MBD2 en MBD3 complex door middel van TAP 
tagging. Hoewel deze eiwitten zijn beschreven als componenten van het Mi-2/NuRD 
complex, tonen onze experimenten aan dat beide eiwitten weliswaar in een Mi-
2/NuRD complex assembleren maar dat MBD2 en MBD3 zelf wederzijds exclusief 
zijn. Verder werd DOC-1, een potentiele tumor suppressor, geidentificeerd als een 
nieuwe subunit van het Mi-2/NuRD complex. Tenslotte werd de arginine 
methyltransferase PRMT5 geidentificeerd als een specifieke MBD2/NuRD interactor. 
PRMT5 bindt direct aan en methyleert de arginine en glycine rijke N-terminus van 
MBD2. In vivo worden MBD2 en PRMT5 samen gerekruteerd naar bepaalde CpG 
eilanden en deze rekrutering is afhankelijk van DNA methylatie. Onze data tonen aan 
dat het Mi-2/NuRD complex in feite een familie van eiwitcomplexen omvat met 
specifieke biochemische en functionele eigenschappen .       
De resultaten zoals die worden beschreven in dit proefschrift hebben ons nieuwe 
inzichten verschaft in de moleculaire determinanten die van belang zijn voor de 
interactie tussen PAH1 en PAH2 en DNA bindende repressor eiwitten.  De 
identificatie van nieuwe Mi-2/NuRD subunits levert hopelijk nieuwe 
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aanknopingspunten op waarmee de transcriptionele repressie mechanismen van 
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